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Abstract
The work described in this dissertation aimed to better understand the genetic and epigenetic factors
influencing chronic kidney disease (CKD) development. Genome-wide association studies (GWAS) have
identified single nucleotide polymorphisms (SNPs) significantly associated with chronic kidney disease.
However, these studies have not effectively identified target genes for the CKD variants. Most of the identified
variants are localized to non-coding genomic regions, and how they associate with CKD development is not
well-understood. As GWAS studies only explain a small fraction of heritability, we hypothesized that
epigenetic changes could explain part of this missing heritability.
To identify potential gene targets of the genetic variants, we performed expression quantitative loci (eQTL)
analysis, using genotyping arrays and RNA sequencing from human kidney samples. To identify the target
genes of CKD-associated SNPs, we integrated the GWAS-identified SNPs with the eQTL results using a
Bayesian colocalization method, coloc. This resulted in a short list of target genes, including PGAP3 and
CASP9, two genes that have been shown to present with kidney phenotypes in knockout mice. To examine
the functional role of a newly identified gene from the integrative analysis, MANBA, we knocked down this
gene in zebrafish. This resulted in pericardial edema, a phenotype seen with kidney developmental defect.
While epigenetic dysregulation has been suggested as a mechanism for the development of many diseases,
little was known about the epigenome of normal and diseased human kidneys. We performed cytosine
methylation analysis in microdissected human kidney tubules in both CKD samples and controls, and found
differentially methylated regions (DMRs) in CKD. These DMRs are further validated in the second cohort.
The DMRs were mostly localized outside of promoter areas and enriched in intronic enhancer regions, and we
found that the DMRs contain consensus-binding motifs for key renal transcription factors (HNF, TCFAP,
SIX2). Furthermore, we found these DMRs correlated with the transcript changes. A network analysis of
these correlated DMR-transcript pairs revealed an enrichment of a fibrosis network highlighted the TGF-β
pathway. In vitro validation experiments established a likely causal relationship between epigenetic changes
and CKD development.
In summary, integration of eQTL analysis with GWAS-identified CKD variants has facilitated the
identification of likely CKD target genes. We discovered that cytosine methylation changes in human kidney
tissue samples in the major fibrotic pathways. Overall, genetic variations as well as cytosine methylation levels
have significant impact on gene expression regulation, possibly downstream organ function, and CKD
development.
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ABSTRACT 
 
UNDERSTANDING CHRONIC KIDNEY DISEASE: GENETIC AND EPIGENETIC 
APPROACHES 
Yi-An Ko 
Katalin Susztak 
The work described in this dissertation aimed to better understand the genetic and 
epigenetic factors influencing chronic kidney disease (CKD) development. Genome-wide 
association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) significantly 
associated with chronic kidney disease. However, these studies have not effectively identified 
target genes for the CKD variants. Most of the identified variants are localized to non-coding 
genomic regions, and how they are related to CKD development is not well-understood. As 
GWAS studies only explain a small fraction of heritability, we hypothesized that epigenetic 
changes could explain part of this missing heritability. 
To identify potential gene targets of the genetic variants, we performed expression 
quantitative loci (eQTL) analysis, using genotyping arrays and RNA sequencing from human 
kidney samples. To identify the target genes of CKD-associated SNPs, we integrated the GWAS-
identified SNPs with the eQTL results using a Bayesian colocalization method, coloc. This 
resulted in a short list of target genes, including PGAP3 and CASP9, two genes that have been 
shown to present with kidney phenotypes in knockout mice. To examine the functional role of a 
newly identified gene from the integrative analysis, MANBA, we knocked down this gene in 
zebrafish. This resulted in pericardial edema, a phenotype seen with kidney developmental 
defect. 
While epigenetic dysregulation has been suggested as a mechanism for the development 
of many diseases, little was known about the epigenome of normal and diseased human kidneys. 
We performed cytosine methylation analysis in microdissected human kidney tubules in both 
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CKD samples and controls, and found differentially methylated regions (DMRs) in CKD. These 
DMRs are further validated in the second cohort. The DMRs were mostly localized outside of 
promoter areas and enriched in intronic enhancer regions, and we found that the DMRs contain 
consensus-binding motifs for key renal transcription factors (HNF, TCFAP, SIX2). Furthermore, 
we found these DMRs correlated with the transcript changes. A network analysis of these 
correlated DMR-transcript pairs revealed an enrichment of a fibrosis network highlighted the TGF-
β pathway. In vitro validation experiments established a likely causal relationship between 
epigenetic changes and CKD development.  
In summary, integration of eQTL analysis with GWAS-identified CKD variants has 
facilitated the identification of likely CKD target genes. We discovered that cytosine methylation 
changes in human kidney tissue samples in the major fibrotic pathways. Overall, genetic 
variations as well as cytosine methylation levels have significant impact on gene expression 
regulation, possibly downstream organ function, and CKD development.  
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CHAPTER 1: Introduction 
1.1 Chronic kidney disease: approaches for understanding the 
disease 
1.1.1. Overview of chronic kidney disease 
The major function of the human kidney is to filter blood and eliminate metabolic waste 
through urine. The healthy human kidney filters 180 liters of blood each day. Most electrolytes 
and small molecules are reabsorbed from the primary filtrate while some of them are secreted in 
the urine. This process requires a large quantity of active molecule transport and associated 
energy expenditure in the kidney. 
Kidney function is mostly measured by filtration capacity (glomerular filtration rate or 
GFR), based on plasma clearance of endogenous creatinine. Chronic kidney disease (CKD) is a 
common condition, estimated to affect 13.6% of the US population [2] and 11 to 13% of the global 
population [3]. CKD is characterized by a 40% decline in eGFR or leakiness of the filter to plasma 
proteins, specifically albumin. More than 75% of persons with CKD have hypertension and 
diabetes in the U.S. [2]. 
CKD is associated with a 3- to 5-fold increase in risk of mortality and is an irreversible 
disease process that culminates in end-stage renal disease (ESRD) [4, 5]. Current treatments for 
ESRD are limited to dialysis and kidney transplantation. Understanding of the mechanisms of 
CKD development is relatively limited with respect to the roles of genetic and environmental 
factors (hypertension, diabetes). No new drugs have been registered for CKD since 2001. 
1.1.2. Genetics and CKD 
A small proportion of CKD cases has monogenetic causes, including cystic kidney 
diseases and glomerular diseases. However, in the majority of cases, CKD is a complex-trait 
disease with both genetic and environmental factors, including diabetes and hypertension [6, 7]. 
One of the key questions in the study of CKD is whether there is evidence suggesting a causal 
role for genetics, specifically whether CKD is heritable. Heritability is the proportion of phenotype 
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variation that is the result of the additive genetic effect of a disease or other condition, e.g. a 
positive or negative correlation of a given trait between parents and offspring. Heritability can be 
assessed through different methods including familial aggregation, adopted children (to 
distinguish environmental factors from heritability), and twin studies. 
Family aggregation studies in the general population have addressed the heritability of 
kidney function, and are also useful for assessing rare variants traveling through pedigrees [8-12]. 
In the Framingham Heart Study offspring cohort with more than 300 families [8], the multivariable-
adjusted heritability estimates were 0.29 for creatinine and 0.33 for eGFR. The heritability of 
eGFR estimated in a normal kidney function Utah pedigree cohort was 0.3 to 0.5 [13]. (Kidney 
traits are further discussed in Chapter 1.2.3.)  
Studies have also revealed that association between kidney disease and family history is 
stronger in African Americans [14, 15] than European-descent Americans [14], suggesting 
potential differences in genetic variation between different populations. In short, kidney function is 
heritable and shows phenotype variations that are specific to different populations. 
Familial linkage analyses have helped identify the causal genes for strongly heritable 
kidney diseases that follow simple Mendelian inheritance patterns. For example, the autosomal 
dominant polycystic kidney disease (ADPKD) gene on chromosome 16 [16], and the Alport 
syndrome gene on the X chromosome [17], were both discovered through genomic linkage 
analysis. Mutations in these genes have low frequency but the effect size for disease risk is large. 
Linkage analysis, a statistical method that associates the function of genes or variants 
with their chromosomal location, has also identified a few genomic loci associated with CKD. 
These include the identification of a chromosome 8 locus link to urinary microalbumin (Fox et al., 
2005), a link between chromosome 19 and 12 with urine albumin to creatinine ratio (UACR; see 
Chapter 1.2.3 for additional detail) (Freedman et al., 2003), a link between the q arm of 
chromosome 7 with diabetic nephropathy [18], a link between chromosome 2q36 and 6q22-23 
with IgA nephropathy [19, 20], and linkage between genes on chromosomes 22q, 5q and 7q with 
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UACR [21-23].  
Although linkage analysis was a successful approach to detect rare genetic variants with 
large effects on disease risk, diseases with different penetrance in affected individuals make 
disease classification difficult (e.g. not all offspring that carry the same genomic mutation will 
develop the same disease) and decrease study power. Pedigree analyses have generated results 
that map genetic loci to kidney diseases using multiple families. However, it is very unlikely that 
each family has the same sets of genetic variants, so the linkage results can conflict and the 
significance decreases. Linkage analysis often identifies rare variants, with large effect size, that 
are segregated within tested families This provides useful insight for monogenic traits, but for 
complex traits, this approach has generated few results and often cannot be reproduced in the 
general population. 
Since complex traits often have multiple genetic factors, these genetic factors should be 
surveyed in general populations that carry the disease, rather than by linkage analysis on family 
pedigrees. To study genetic variants that are associated with specific diseases in the general 
population, the “common disease, common variant” (CD-CV) hypothesis was developed in the 
1990s. The CD-CV hypothesis proposes that genetic variants in normal individuals contribute to 
overall risk of complex-trait diseases. It was first described in a few publications [24-26], then 
supported by comprehensive empirical data [27]. Later the CD-CV hypothesis was advanced 
through the completion of the human genomic map [28, 29], generation of public SNP databases 
[30], and the International HapMap project [31, 32].  
Based on the CD-CV hypothesis, GWAS were devised to study the association between 
common variants and complex-trait phenotypes. GWAS with genotyping arrays have facilitated 
the identification of multiple loci associated with kidney function. Genotyping arrays are designed 
so that through statistical inference, they can recover most of the HapMap and 1000 Genomes 
cataloged variants. The array is an economical substitute for whole-genome sequencing [33]. 
More than 100 loci have been identified, and these variants show strong and reproducible 
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association with CKD. The majority of the variants are localized to non-coding regions of the 
genome [34]. More detailed development of GWAS can be found in Chapter 1.2. 
The detection of genetic variants that exert small effects or appear with very low 
frequency in complex-trait disease development requires very large study cohorts for sufficient 
statistical power. These variants may therefore be missed by GWAS with current sample size. To 
date, the identified genetic variants explain only a small fraction of the heritability of CKD. Single 
nucleotide polymorphisms (SNPs) associated with kidney function explain only approximately 3% 
for eGFR thus far [35-38].  
Since the majority of the GWAS-identified variants are localized to the non-coding 
regions of the genome, it is unclear which genes are affected by the genotypic changes. In order 
to develop a more complete understanding of the genetic basis for CKD, CKD-associated SNPs 
need to be tied to their target genes. With the advance of microarrays and RNA sequencing, it is 
feasible to assess genome-wide gene-expression changes. A few studies have shown the 
heritability of gene-expression traits [39-42], and thus we can use gene expression as a 
quantitative trait for performing expression quantitative trait loci analysis (eQTL), a method that 
will be discussed further in Chapter 1.3. CKD-associated SNPs can be more accurately 
understood by using eQTL to link to potential target genes, and could be studied for their relevant 
biological functions.  
In Chapter 2, I focus on understanding the genetics of CKD, with an aim of identifying 
target genes in GWAS studies. I use eQTL analysis to identify target genes for the CKD GWAS 
hits. Methods used in this study have identified potential target genes for mechanistic and causal 
studies of kidney disease development.  
1.1.3. Epigenetics and CKD 
A plausible mechanism that could explain the missing heritability for phenotypes is 
epigenetic change [43]. In general, epigenetics studies chemical modification changes in the 
genome that do not alter DNA sequences. Epigenetic traits are DNA-sequence-independent 
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transgenerational changes, brought on by changes to the environment of the affected individual 
that propagate environmental effects on phenotypic development. Transient metabolic changes, 
for example, can result in long-term phenotypic alterations by epigenetic reprogramming.  
One popular hypothesis for the missing heritability is the “developmental origins of adult 
diseases” hypothesis, also referred to as the Brenner-Barker hypothesis or fetal programming. 
For example, an adverse nutritional environment during development has been shown in animal 
models to be associated with worse lifetime outcomes including blood pressure, metabolic and 
renal traits, even after the subject animals have been separated from the adverse conditions.  
In addition to fetal programming, the effect of poor glycemic control can be detected even 
a quarter-century after cardiovascular and kidney disease development, a phenomenon called 
“hyperglycemic memory.” More detail is provided in Chapter 1-4. 
To understand whether epigenetic changes potentially contribute to CKD development, I 
performed genome-wide cytosine methylation analysis of microdissected human kidney samples. 
I discuss this work and its results in Chapter 3.  
 
1.2 Genome-wide association studies 
1.2.1. The history of genetic mapping 
Genetic mapping of inheritance dates to the late 19th century with Gregor Mendel’s 
publication of the laws underlying inheritance patterns he observed in Pisum sativum [44]. 
However, in the beginning of the 20th century, cases involving more than two traits were found 
not to follow Mendelian random segregation principles consistently. For example, while eye and 
body color in Drosophila melanogaster tend to pass down together, this is not always true. These 
inconsistencies motivated researchers to look into the genetic mechanisms underlying multiple-
trait inheritance.  
Around the same time, cell biology was progressing quickly along with increased 
microscope resolution. Frans Alfons Janssens discovered the crossing-over of genes during 
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meiosis and termed the process “chiasma.” Thomas Hunt Morgan found that this process 
explained his own observations in D. melanogaster cross-breeding experiments. He adopted the 
evidence collected by Janssens and developed the theory of genetic linkage. Morgan stated that 
as a result of meiotic recombination, any markers that are correlated in segregation are located 
close to one another in the genome [45]: 
If the materials that represent these factors are contained in the chromosomes, 
and if those factors that “couple” be near together in a linear series, then when 
the parental pairs (in the heterozygote) conjugate like regions will stand opposed. 
There is good evidence to support the view that during the strepsinema stage 
homologous chromosomes twist around each other, but when the chromosomes 
separate (split) the split is in a single plane, as maintained by Janssens. In 
consequence, the original materials will, for short distances, be more likely to fall 
on the same side of the split, while remoter regions will be as likely to fall on the 
same side as the last, as on the opposite side. 
Morgan highlighted the idea that traits are linked and his student Alfred Sturtevant took 
the analysis forward. He realized that all D. melanogaster have the same chromosome length. 
This facilitated construction of a genetic map, because the frequency of specific phenotypic pairs 
among all offspring could be used to calculate the relative distance of the relevant genetic 
markers. He proposed that the distance between any two genetic markers on a D. melanogaster 
chromosome was inversely related to the ease of separating the traits. Sturtevant successfully 
tested the hypothesis and produced the first chromosome map, which included the sex-linked 
genes in the correct order and relative spacing [46]. The non-random assortment of genetic 
markers in the chromosomes was later termed linkage disequilibrium (LD) [47].  
Since the first genetic mapping of Drosophila traits, geneticists have mapped numerous 
other model organisms by intensive interbreeding for the mutants of detectable phenotypes. 
However, this cannot be carried out in humans for obvious ethical reasons. There were some 
successes in identifying linkage, including the first autosomal linkage in human, the Lutheran 
blood group antigen system [48]. Then, in 1980, Botstein suggested the first systematic method 
to map genes, using an existing method involving restriction fragment length polymorphisms 
(RFLPs). RFLP detects DNA polymorphisms through restriction endonucleases. The restriction 
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endonucleases are sequence-specific restriction enzymes that cannot recognize and digest the 
DNA sequences when there is polymorphism in the DNA sequence. Applying this method to 
human genomic DNA would result in different lengths of DNA sequence, indicating the presence 
of polymorphisms [49, 50]. Combining the polymorphisms as genetic markers with pedigree 
information, linkage of human genetic diseases was enabled, for example Huntington’s disease 
[51], adult polycystic kidney disease [16], cystic fibrosis [52-54], and retinoblastoma [55, 56].  
Since the 1980s, genetic mapping has identified mutations in thousands of genes that are 
associated with Mendelian diseases through relatively low-density panels of markers. However, 
common diseases exhibit more complex inheritance patterns in the general population, and 
traditional gene-mapping methods cannot identify genetic causes effectively for such common 
diseases as hypertension, cardiovascular diseases, obesity, and CKD. 
1.2.2. GWAS methods  
GWAS examines genetic variants across the human genome to identify associations 
between variants and phenotypes. Study power is one of the main considerations in designing a 
GWAS. Study power is the probability of the null hypothesis being correctly rejected. Large 
sample size is necessary to provide enough study power, especially when the association 
between a single variant and the disease is weak. 
Association studies are carried out in two stages. In the first stage (the discovery phase), 
the association of variants and phenotypes is determined. Variants that are identified if they have 
statistically significant allele frequency differences associated with disease phenotypes and 
quantitative traits. In the second stage (the replication phase), significantly associated markers 
from the discovery phase are evaluated for association in additional independent study samples 
that resemble the initial discovery sample. Replication serves to confirm association and to detect 
potential bias. The replication analyses reduce the incidence of technical mistakes and 
spuriousness in the identified associations. 
To date, more than 88 million genomic variants have been cataloged in the 1000 
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Genomes Project [57]. Directly assaying all known common polymorphisms is inefficient and 
impractical, because many variants are highly correlated due to LD. Genotyping a reduced set of 
variants in one strongly linked block can be used to infer the remaining variants through genotype 
imputation (discussed below). It is therefore important to select variants that can achieve 
genome-wide coverage within a feasible budget. Generating genetic maps based on direct 
genomic distance is rarely used for marker selection (e.g. using evenly spaced markers across 
the autosomal chromosome). On the other hand, cataloged common human sequence variations 
are more commonly used to calculate LD and select genetic markers for the genotyping arrays 
[58, 59]. 
In the 1990s, array-based genotyping platforms assayed fewer than 10,000 SNPs, but 
this has subsequently increased to between 300,000 and 5,000,000 SNPs per array in recent 
years. GWAS efficiency and statistical power can be improved through genotype phasing and 
imputation. Phasing is a method to estimate haplotype. When genomic variants are genotyped, 
we observe pairs of alleles, but the strand and haplotype (a series of genomic variants that are on 
the same chromosome) to which they belong are unknown; in other words, we cannot identify the 
parent from which the individual acquired the haplotype. 
Once the haplotype is phased, imputation is performed. Imputation is the statistical 
inference of unobserved genotypes using a set of observed-genotype-phased haplotypes as a 
reference [31, 33, 57, 60, 61]. This technique allows us to estimate the genetic markers that are 
not directly genotyped. The HapMap, 1000 Genomes Project and Haplotype Reference 
Consortium have produced extensive LD maps, and there are several methods to impute 
genotypes based on these LD relationships [62-65]. When combining genotype data from 
different studies, often the genotype data are generated on different platforms. By imputing 
genotypes, meta-analysis can infer genotypes that are unknown in some of the studies, allowing 
GWAS to increase sample size and power.  
Interpretation of the results of large association studies faces the statistical difficulty of 
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type I errors, where incorrect rejection of the null hypothesis yields false positive results. To cope 
with false positives, a multiple-testing corrected p-value is typically used. One of the most 
frequently used is to take the Bonferroni correction for multiple tests, where the cutoff p-value of 
0.05 is corrected by the approximate one million independent tests (the number of common 
variants tested in the genomes of individuals of European ancestry) to generate the threshold [66, 
67]. 
Hundreds of traits have been examined by GWAS, and variants that have reached 
genome-wide significance can be accessed at the GWAS Catalog supported by the National 
Human Genome Research Institute (NHGRI) and the European Bioinformatics Institute (EMBL-
EBI) [34]. 
The majority of GWAS-identified loci are non-coding variants and this limits the ability of 
GWAS to identify the causal variants and to link these genetic variants to the disease 
mechanisms. 
1.2.3. GWAS and chronic kidney diseases 
The National Kidney Foundation defines chronic kidney disease according to any of the 
following criteria: pathologic kidney abnormalities, persistent proteinuria, other urine abnormalities 
(e.g., renal hematuria), imaging abnormalities, and eGFR <60 mL/min/1.73 m2 on two occasions 
separated by more than 90 days [68]. CKD is classified in five stages, where stage 1 is the 
mildest form and stage 5 is the most severe with eGFR <15 mL/min1.73m2. When stage 5 CKD is 
treated by dialysis or kidney transplant, it is also categorized as ESRD or renal failure. The 
current treatment options for ESRD are limited to dialysis or kidney transplant. 
 Most of these measurable traits of kidney dysfunction can be used as a quantitative trait 
in GWAS studies, including eGFR, proteinuria, histologic morphology, and metabolites observed 
in urine. eGFR is estimated using equations that incorporate endogenous filtration markers, for 
example serum creatinine (SCr) or cystatin C (CysC). Case-control studies can also use eGFR to 
define CKD as patients with eGFR below 60 mL/min/1.73m2. The CKDGen Consortium published 
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a meta-analysis of multiple cohorts with the largest sample size to date for kidney function eGFR 
in 2016. In total, 175,000 individuals were included and 53 loci were identified (29 known and 24 
novel loci; most of these variants are associated with eGFRcrea, one with eGFRcys and four with 
CKD) [69]. 
Another key marker for CKD is urinary albumin. Albumin is a 66 kDa protein that 
circulates in the blood stream and cannot pass through the glomerular filtration barrier. However, 
when kidney structural integrity of the glomerular filtration barrier is injured or albumin 
reabsorption along the proximal tubules is impaired, larger proteins like albumin will leak into the 
urine. 
To measure proteinuria, a frequently used method is to collect samples at only one time 
point and measure the albumin and creatinine concentrations. Creatinine level is used for 
normalization for the albumin because albumin levels will vary with urine concentration. This 
method yields the urine albumin-to-creatinine ratio (UACR); microalbuminuria is defined as 30-
300 mg/g, and macroalbuminuria as UACR >300 mg/g. 
In a GWAS study examining UACR, a total of 67,000 samples was used for meta-
analysis and independent replication in more than 51,000 samples, which identified 1 locus with a 
missense variant in the cubilin gene (CUBN) [70, 71]. As mentioned earlier, CKD is defined by 
reduced eGFR or by microalbuminuria. Several attempts were made to validate eGFR-associated 
SNPs in UACR; however, none of the eGFR-associated SNPs were associated with UACR or 
albuminuria, suggesting different genetic components for the two traits [72, 73]. 
 Several specific etiologies of CKD were tested in case-control studies, including diabetic 
kidney disease (DKD), ESRD, IgA nephropathy, steroid sensitive nephrotic syndrome (SSNS), 
and membranous nephropathy (MN). 
It is estimated that approximately 45% of CKD patients have diabetic kidney disease 
(DKD), which is diabetes accompanied by CKD markers including increased UACR and 
decreased eGFR. The Diabetes Control and Complications Trial (DCCT)/Epidemiology of 
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Diabetes Interventions and Complications (EDIC) performed GWAS in 1,304 participants and 
found 13 independent loci [74] in type I diabetes; however, there were no SNPs that reached 
genome-wide significance. Similarly, no variant reached genome-wide significance in a trans-
ethnic meta-analysis of type II diabetes in the Family Investigation of Nephropathy and Diabetes 
(FIND) cohort in 2008 [75].  
In 2015, 1 locus on chromosome 6 reached genome-wide significance in a study of more 
than 6,000 unrelated individuals in the FIND cohort for DKD, and this result was replicated in a 
separate study of more than 7,000 individuals [76]. A meta-analysis showed 21 significant loci, 
which replicated loci that were close to genome-wide significance in both Pezzolesi et al and the 
FIND study [77]. And one significant locus was found with combined discovery and replication 
cohorts [78]. Other studies have discovered loci associated with type I or type II diabetes-
associated ESRD [78-80]. However, there was no overlap between DKD- and CKD-identified loci.  
The disparities among studies possibly arose from the use of different diagnostic 
parameters for DKD. Some studies used diabetes mellitus (DM) combined with eGFR to classify 
DKD, while others combined DM with albuminuria levels. The other possible reason may be due 
to differences in environmental effects such as glycemic control, DM duration, and blood pressure 
control, as they influence disease development and perhaps the association results.  
 Important loci on chromosome 22 have been discovered using admixture mapping 
associated with non-DM ESRD in African American cohorts [81, 82]. This locus was later fine-
mapped to three variants close to the APOL1 gene, which showed an evolutionary advantage of 
resistance to trypanosome-mediated sleeping sickness in West Africa [83, 84].  
Finally, IgA nephropathy (IgAN) is characterized by the deposit of IgA immune complexes 
in the glomerular mesangium, which causes progressive kidney injury [85]. The genetic 
component of IgAN has recently been shown by many linkage studies as well as GWAS results. 
Two major GWAS meta-analyses replicated 9 loci and identified 6 novel loci [86, 87]. 
 A collection of CKD associated SNPs is summarized in Appendix 1, which lists of 110 
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independent loci of GWAS findings for different kidney disease associated traits; all neighboring 
SNPs with LD ≥ 0.2 were removed. 
 
1.3 Expression quantitative locus analysis (eQTL) 
1.3.1. The development of eQTL analysis 
As discussed in the preceding section, the majority (around 90%) of the variants 
identified in GWAS are in non-coding regions of the genome. The non-coding variants present 
special challenges for research, because predicting functional consequences of genetic variants 
in non-coding regions has been difficult. Identifying quantitative phenotypes that are associated 
with these variants (QTL) can facilitate the mechanistic studies for disease development, for 
example gene expression levels, or expression QTL (eQTL).  
The systematic measurement of gene expression levels through microarray methods 
facilitated the first few major eQTL analyses, proceeding from the yeast [88], maize [89], mouse 
[89], to human genome [90], and the eQTL method has been applied to several diseases. 
However, most eQTL analyses of human samples were performed in immortalized cell lines or 
circulating cells [91]. The transcriptome is tissue-type specific, thus surrogate cell types cannot 
represent organ-specific regulation of gene expression by variants. There is a large number of 
ubiquitously expressed genes that show shared regulation of gene expressions in the genome, as 
shown in GTEx consortium [92] and other international projects that have generated 
comprehensive catalogs of human eQTL maps. 
Adopting transcription levels measured by RNA-sequencing in eQTL was advanced 
through the work of the GTEx consortium [92]. The application of RNA-sequencing enabled the 
quantification of transcript levels, identification of isoforms, and examination of allele-specific 
expression, as well as long non-coding RNAs and novel transcripts in a much higher resolution 
than the array-based method [91, 93]. 
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1.3.2. eQTL analysis  
eQTL mapping examines the genotype of a genetic locus that is significantly associated 
with the transcript or gene expression levels local (cis) or distal (trans) to the transcription start 
site of each gene. The cis-eQTL concept is illustrated in Figure 1-1, where the distance is 
conventionally specified as 1Mb from the transcription start site of each gene, as most regulatory 
control takes place in the vicinity of genes. As shown in the figure, an eQTL may contain multiple 
genetic variants that tag the actual causal variant or variants in close LD, which accounts for the 
genotype-dependent gene expression.  
Stringent genotype quality control (QC) is crucial to reduce the incidence of technical 
problems and spuriousness in the identified associations. After QC, genotypes are subject to 
phasing and imputation using large reference panels to infer the untyped genotypes. It also 
increases the accuracy of imputation for variants with lower frequencies [94-96]. Gene expression 
analysis using RNA-seq instead of microarray to quantify the transcript expression level provides 
a few advantages. RNA-seq provides transcript isoform expression as well as information for 
allele-specific expression. 
Figure 1-1 | Illustration of cis-eQTL 
The genetic locus where the genotype of a variant is significantly associated with the gene 
expression levels with one or more genes in a defined distance. Gene expression levels are the 
quantitative phenotype and the genetic loci controlling the phenotypic changes are identified by 
comparing gene expression and genotypic data from the same set of samples and determining the 
associations between them. 
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eQTL analysis of peripheral blood samples that the number of genes with identified local 
eQTLs rose from around 5% in 100 samples to approaching 50% of all genes after meta-analysis 
using several thousand samples [97]. This establishes that increased sample size can increase 
resolution of variants explaining the transcript variance [97, 98].. 
Recent reports from GTEx with 44 tissue types showed that although increased sample 
size is positively related to more shared cis-eQTL, weaker associations still remain that are 
unique to the individual tissues and have higher effect size than shared eQTL [98]. 
 
1.3.3. Finding colocalization of GWAS and eQTL loci 
The general model used to understand GWAS signals is that a causal variant is localized 
to a regulatory region in the disease-causing cell type. The variant alters TF binding and further 
affects the expression level of the genes. 
One way to prioritize studying regions associated with potential causal variant is to 
combine statistical association of genetic variants with gene expression, and with complex traits, 
by colocalization of signals. 
An important example of the integrative analysis from GWAS to eQTL to phenotype was 
demonstrated with the FTO locus. This locus was discovered to be associated with obesity in 
several GWAS [99, 100], with the reproducibility suggesting that it was the most significant signal 
for obesity. The obesity-associated FTO region was shown to have enhancer properties identified 
using histone mark modifications as well as enhancer assays [101].  
The FTO region was also demonstrated to interact with the promoters of the IRX3 gene 
through circular chromosome conformation capture followed by sequencing (4C-seq) [102]. In 
short, the FTO region regulates the IRX3 gene through its enhancer activity. The rs1421085 T-to-
C variant in the obesity-associated FTO region was shown to disrupt a conserved ARID5B 
repressor motif. Under the normal condition of the T allele at rs1421085, ARID5B binds to the 
sequence and suppresses the enhancer, causing a drop of IRX3 and IRX5 expression. These 
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changes shift the mesenchymal progenitors from white adipocytes, browning to beige adipocytes 
(lipid storage), and leading to decreased mitochondrial respiration and thermogenesis with 
increased adipocyte size. When there is disruption of the ARID5B binding site with C allele at 
rs1421085, IRX3 and IRX5 expression increases and the pre-adipocyte differentiates into lipid-
storage white adipocyte. [101].  
Studies have shown that trait-associated GWAS SNPs are significantly more likely to be 
eQTLs than expected by chance [103]. To highlight the target genes of GWAS SNPs, we can co-
localize the eQTL and GWAS signals. The colocalization of genetic variant signals implies that 
the gene with eQTL at the same locus as GWAS can influence the disease trait [104]. Several 
methods have been proposed, and each has a different hypothesis and approach for mapping the 
location and signals from the summary statistic in eQTL and GWAS.  
Among many GWAS and eQTL integration studies, I reviewed two that were used in 
Chapter 2 as they provided superior understanding of colocalization. The Sherlock method [105] 
uses Bayesian statistics to match the association signals from GWAS and eQTL for individual 
genes, in order to distinguish whether the significance are coming from the same variant. A 
second method, Coloc [106], also based on Bayesian statistics, tests the hypotheses that the 
colocalizations of GWAS and eQTL signals represents a causal or coincidental relationship. 
These methods explain the significance of using both eQTL and GWAS summary 
statistics to assist in identification of potential causal variant(s) at a specific locus. To further 
narrow down and identify the potential disease-causing variants, we need to further annotate the 
genome with regulatory elements in a cell-type specific manner, including histone tail 
modifications and cytosine methylation levels. 
 
1.4 Epigenetics 
1.4.1. Epigenetics in chronic kidney disease 
As GWAS only explains 3 % of CKD heritability, there is a need to understand the 
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“missing” heritability. Increasing the samples size of GWAS cohorts, using denser genotyping 
platforms and different ethnic groups will be critical for this effort. Another potentially important 
mechanism for understanding missing heritability is transgenerational epigenetics. 
There is a large variation in the number of nephrons in the human kidney, ranging from 
approximately 200,000 to 2 million. The number of nephrons at birth is inversely correlated with 
the risk of hypertension and CKD [107]. Low nephron count is correlated with low birth weight 
[108], which often results from intrauterine malnutrition [109, 110]. Low nephron number causes 
increased glomerular pressure on the remaining nephrons, and the increased workload on each 
glomerulus can induce microalbuminuria and glomerulosclerosis, resulting in nephron loss and 
renal injury [111].  
Intrauterine malnutrition is associated with metabolic syndrome, hypertension, and renal 
disease development by fetal programming [111-114]. A direct correlation of low birth weight to 
microalbuminuria in type I diabetes has been established in the general population [115]. Rodent 
models of intrauterine growth retardation have indicated that lack of nutrient or oxygen availability 
results in the development of salt-sensitive hypertension and microalbuminuria [116]. Together, 
these results indicate that the epigenome could be an important mediator of long-lasting 
intrauterine environmental effects, particularly because the epigenome is plastic during 
development [117-119]. 
In addition, several environmental factors have been shown to have a long-lasting effect 
on CKD development [120]. Environmentally induced epigenetic modification could represent a 
plausible mediator explaining the impact of environmental factors on CKD development. Although 
differentiated cells have a stable epigenome, lately the cellular memory or programming effect of 
the environment has been described to extend beyond development as well (Fig. 1-2). 
Epigenetics can explain missing heritability in cases of transgenerational changes. 
Trangenerational epigenetic effects have been shown in rodent models [121, 122] and also 
proposed in a two human studies [123, 124]. The association between intrauterine exposure to 
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maternal diabetes has been established as having an adverse effect on BMI and insulin secretory 
function in offspring [125]. The transgenerational effect was further studied in a Pima Indian 
(U.S.) cohort with or without intrauterine exposure to diabetes. The Pima Indian study showed 
that the risk can be explained by cytosine methylation differences that are enriched in type 2 
diabetes, maturity onset diabetes of the young (MODY), and Notch pathways [126].  
One key question is how does nutrient availability change the epigenome? Most 
chromatin-modifying enzymes require substrates or cofactors that are intermediates of cell 
metabolism [127-130]. For example, acetylation by histone acetyltransferases depends on the 
local subcellular acetyl-CoA concentration [131, 132]. In vitro evidence supports the conclusion 
that fluctuations of metabolite levels modulate activities of chromatin-modifying enzymes, thereby 
influencing chromatin dynamics [133-135].  
Cells and tissues are sensitive to epigenetic shift while the epigenome is plastic and 
being established during development and differentiation. Change in the epigenome during 
development plays an important role in phenotype development later on, by modulating how cells 
respond to stimuli [136, 137]. For example, while podocytes without an essential component of 
H3K4 methyltransferase develop into functionally competent cells, it was shown that they have an 
abnormal response to environmental stressors (e.g. aging) [138]. Recent studies suggest that we 
can predict cellular aging based on the epigenetic signature [139-142]. This indicates that the 
epigenome could provide a traceable link between the genome and the environment. In short, the 
epigenome is emerging as a biochemical record of relevant life events.  
1.4.2. Epigenetics and CKD development in mouse models 
Recent research supports the role of epigenetics in CKD development. Bechtel et al. 
showed differences in the cytosine methylation profiles of fibroblasts isolated from control and 
CKD mouse kidneys [143]. Using a folic acid-induced kidney fibrosis model, the investigators 
showed that hypermethylation of a guanosine triphosphatase-activating protein, RASAL1, causes 
increased Ras activation in fibroblasts, resulting in fibroblast proliferation and fibrosis 
  
 
18 
development. Genetic deletion or chemical inhibition of DNMT1 is able to reduce fibrosis 
development in the folic acid-induced kidney fibrosis model. Future studies using DNMT inhibitors 
in other progressive kidney disease models, as well as cell-type-specific Dnmt1 deletion in mice, 
will aide in elucidating how changes in cytosine methylation contribute to kidney fibrosis 
development. 
The contribution of histone deacetylase (HDACs) has also been described in different 
mouse models of acute and chronic kidney injury [144-150]. The HDAC inhibitor Trichostatin A 
(TSA) ameliorates proliferative glomerulonephritis [151], long-term glomerulosclerosis [152, 153], 
and proteinuria in a nephrotoxic serum nephritis model [152]. Pretreating mice with valproic acid, 
a class I-selective HDAC inhibitor, was highly effective in reducing proteinuria as well as sclerosis 
in the doxorubicin-induced focal segmental glomerulosclerosis model [154]. Two separate studies 
have shown that HDAC inhibitors can also attenuate diabetes-induced renal hypertrophy and 
renal damage in rodents [155, 156]. 
Together, these chemical inhibitor-based studies strongly suggest that histone 
deacetylases play a major role in CKD development. The proposed mechanism is that HDAC 
inhibitors are involved in reactivating major developmental pathways and promoting tissue repair 
after injury. Unfortunately, HDAC inhibitors, similar to many inhibitors, have cell-type specificity 
issues. Therefore, follow-up studies using genetically engineered site-specific knockout animals 
will be essential to determine the role and contribution of histone acetylation in kidney fibrosis.  
Cell-culture-based studies from the Natarajan and El-Osta laboratories have indicated 
that cells that are grown in a high-glucose medium develop rapid and persistent changes in their 
histone tail modification patterns [157-160]. In cultured aortic endothelial cells, transient 
hyperglycemia caused changes in H3K4me1 on the promoter of the p65 subunit of nuclear factor-
κB, and subsequently was associated with increased p65 transcript levels. The expression of p65 
was increased in endothelial cells even several days after they were returned to a normal glucose 
medium.  
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A similar mechanism has also been shown in diabetic mice. The sustained 
proinflammatory phenotype observed in vascular smooth muscle cells cultured from type 2 
diabetic db/db mice was associated with reduced levels of the repressive mark H3K9me3 on the 
affected inflammatory gene promoters [161]. Treatment of glomerular mesangial cells with 
transforming growth factor (TGF)-β1 or high glucose could lead to changes in key active and 
repressive histone modifications at the promoters of inflammatory and fibrotic genes [162, 163]. 
These observations link episodes of hyperglycemia with a persistent increase of inflammation and 
fibrosis, which are important characteristics of diabetic kidney disease. 
1.4.3. Epigenetics and CKD development human studies 
Large-scale human studies showing epigenetic differences in CKD have not been 
published, because the epigenome is cell-type specific and therefore human kidney tissue and 
kidney cell lines are necessary for experiments. There are a few human epigenome-wide-
association studies that used peripheral blood mononuclear cells or other surrogate cell types. 
Sapienza et al [164] described differences in cytosine methylation profiles of diabetic patients with 
and without ESRD. Infinium HumanMethylation27 BeadChip arrays were used to determine 
cytosine methylation changes. Although there was significant patient heterogeneity, Sapienza et 
al identified close to 110 loci with statistically significant methylation differences in ESRD samples 
compared with those without ESRD. Most loci showed lower methylation levels in the ESRD 
cases, and many of the differentially methylated regions were in close proximity to genes that 
previously had been shown to express differently in patients with kidney diseases. Although this 
is an important first step to understand the epigenome of CKD, future research will be required to 
determine whether markers found in human urine correlate to epigenetic changes in renal 
epithelial cells, which can further be used to develop disease markers using non-invasive sample 
collecting method. 
Another study, by Ciavatta et al [165], examined the potential contribution of the 
epigenome to antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. ANCA disease is 
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associated with spontaneous development of autoantigens against myeloperoxidase (MPO) and 
proteinase 3 (PR3) proteins. Ciavatta et al found that H3K27me3, a chromatin modification 
associated with silenced promoters, was decreased at the PR3 and MPO promoter areas in 
ANCA patients compared with healthy controls. H3K27me3 was also associated with decreased 
cytosine methylation of PR3 and MPO CGI promoter areas. The investigators proposed that 
normally higher RUNX3 levels were responsible for recruiting H3K27 methyltransferase, a subunit 
of enhancer of zeste homolog 2 (EZH2), to PR3 and MPO loci. Loss of RUNX3 expression is a 
plausible cause for the loss of H3K27 methylation and the expression of MPO and PR3 in ANCA 
patients. This was an elegant illustration that epigenetic modifications associated with gene 
silencing are perturbed at ANCA autoantigen-encoding genes, potentially contributing to 
autoimmunity development. 
Future studies could determine whether similar mechanisms play a role in other 
autoimmune diseases as well. In Chapter 3, we discuss the regulation of gene expression in the 
pathogenesis of CKD through cytosine methylation.  The alterations in both gene expression and 
cytosine methylation in the TGF-β pathway (TGFBR3, SMAD3, SMAD6) were observed in the 
CKD patient samples, and these genes were known to be the key regulators of kidney fibrosis 
development and have important roles in CKD development [166]. 
1.4.4. Epigenetics Overview 
The epigenetic mark is characterized by chemically modified DNA or associated proteins. 
Epigenetic marks include cytosine modification (mainly methylation) and histone tail modification, 
which are changes caused by nutrition and other environmental factors [167, 168]. The epigenetic 
mark is inherited during cell division to maintain cell identity, thereby mediating between the 
stably inherited genome and the changing environment. Characterization of the epigenetic mark 
has played a major role in defining cell-type-specific gene expression. 
A classic transcription unit in a multicellular eukaryote contains both clusters of proximal 
promoter elements and several types of cis-acting regulatory sequences including insulators, 
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promoters, enhancers, silencers, and locus-control regions [169]. Insulators border and separate 
transcriptional units. Promoters are usually located at the 5' end of transcription start site, the 
minimal sequences required for accurate transcription initiation. The promoter region can 
encompass a cluster of cytosine-guanine nucleotide pairs within the linear sequence, known as 
CpG islands (CGI) [169, 170]. 
For gene transcription to occur, not only promoters but also long- and short-range 
regulatory regions are needed. These cis-type gene-regulatory regions are often highly cell-type-
specific. Simultaneous binding of transcription factors (TFs) to each other and to the long- and 
short-range regulatory regions results in genomic DNA loops that join distant regulatory DNA 
sequences together (Figure 1-2) [171, 172].  
Enhancers are also of critical importance, and can be located from between a few 
kilobases (short-range) to hundreds of kilobases (long-range) away from the regulated gene [169, 
173, 174]. Enhancers can be found in the opposite DNA strand, downstream of the regulated 
gene, or at intronic regions. Enhancers usually show significant enrichment for the binding of cell-
type-specific TFs [174]. TF binding, or the presence of multiple enhancers, is critical for regulating 
the optimal transcription strength following an external stimulus. However, sometimes the loss of 
even one enhancer can result in loss of expression level of a gene [175].  
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While the critical importance of enhancers has been increasingly appreciated, genome-
wide identification of enhancers has been exceedingly difficult. Recent advances in epigenetics, 
sequencing and computational methods have helped to define these important gene regulatory 
regions and will be discussed in detail in this chapter.  
Histone modification: The DNA in the cell nucleus is wrapped around small, positively 
charged proteins called histones, to form a larger organized structure called chromatin. When 147 
base pairs of DNA are wrapped around histones, it forms a compact structure called a 
nucleosome [176, 177]. In addition to DNA, nucleosomes are comprised of a histone octamer 
consisting of two copies each of the core histones H2A, H2B, H3, and H4 [175]. 
Nucleosomes play important roles in compacting DNA into the nucleus. When the 
nucleosome is in condensed condition, called heterochromatin, it is inaccessible to transcription 
factors and transcriptionally inactive [178]. Modification of the amino acids in the histone tails 
appears to be central to the processes that regulate transcription, including methylation, 
acetylation, phosphorylation, and ubiquitination [179]. The histone code hypothesis proposes that 
Figure 1-2 | The eukaryotic transcription unit. 
The eukaryotic transcription complex is characterized by a combination of transcription 
factors binding to promoters and one or more looping enhancers. Enhancers can be 
upstream, downstream or intronic. Enhancers are cell-type-specific. Both enhancer looping 
and TF binding are essential for messenger RNA transcription. Different chromatin regions 
are characterized by different histone tail marks. CTCF, CCCTC-binding factor. TF, 
transcription factor. 
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chromatin-DNA interaction (i.e. the gene regulatory complex) is guided by histone tail modification 
[170]. There are molecular histone code “writers” that establish these modifications, and 
“readers”, the enzymes that use these histone tail modifications to assign gene regulatory 
function to DNA [180-183]. More than 60 histone modifications have been described [184, 185], 
although some are redundant and the overall set can be simplified into 10-15 different patterns, 
each with specific gene regulatory functions (Table 1-1).  
Functional genomic elements are identified through sequence-association with histone 
modification, TF binding and DNaseI hypersensitivity [186]. Cell-type-specific gene regulation can 
be understood by defining the cellular histone code (the epigenome). The pioneering ENCODE 
and Roadmap Epigenome projects have resulted in the ongoing characterization of cell-type-
specific annotations of gene regulatory regions through the use of cultured human cell lines and 
human tissues [187].  
Transcription factor binding is a key characteristic of a regulatory region; gene regulatory 
regions are mostly open and nucleosome-free. Nucleosome-free DNA is sensitive to DNaseI 
digestion, allowing the identification of gene regulatory regions by DNaseI hypersensitivity 
methods [188-190]. Nucleosomes directly adjacent to DNaseI-hypersensitive sites are 
characterized by specific histone tail modifications.  
For example, H3K4me3 in combination with H3K4me2 and H3K4me1 H3K27ac usually 
marks active promoter areas. On the other hand, H3K27me3 and H3K9me3 usually mark inactive 
promoters. H3K4me1, H3K27ac and H3K9ac marks together are associated with enhancer 
activity, and H3K36me3 and H3K20me1 mark transcribed regions both for coding and non-coding 
transcripts [170, 191]. The binding of the transcriptional repressor, CTCF, defines insulator areas 
that separate different transcriptional units.  
Table1-1| Gene regulatory function of histone marks  
Chromatin Mark Chromatin State 
CTCF§ Insulator/repetitive/CNV¶ 
H3K27me3 Poised promoter/repressed promoter 
H3K36me3 Transcription transition and elongation 
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H4K20me1 Transcription transition 
H3K4me1 Enhancer 
H3K4me3 Promoter 
H3K4me2 Promoter/enhancer 
H3K27ac Active enhancer 
H3K9ac Active Promoter 
§ CTCF, CCCTC-binding factor; ¶ CNV, copy number variation 
 
Combinations of histone marks further tune gene regulatory regions within the genome. 
In particular, H3K4me1 and H3K27ac together have been shown to mark the location of cis-
regulatory active enhancers. H3K9me3 and H3K20me3 histone tail modifications are used to 
locate satellite, telomeric, and repeat regions. In embryonic stem cells, large genomic regions 
have histone modifications with characteristics opposite to those seen in differentiated cell types. 
For example, many developmentally important transcription factor-encoding regions in embryonic 
stem cells contain both the active mark of H3K4me3 and the transcriptional repressor mark of 
H3K27me3. These regions are called bivalent domains [192-194]. Promoters of key 
developmental transcription factors that control differentiation typically have bivalent domains 
[195-197].  
During differentiation, cells will take on either the active or the repressive mark depending 
on which pathway they follow. Adding methyl groups to histones is attributed to three families of 
enzymes that catalyze the addition of methyl groups donated from S-adenosylmethionine to 
histones. The SET domain-containing proteins [198], DOT1-like proteins, have been shown to 
methylate lysines (K) [199, 200], and members of the protein arginine (R) N-methyltransferase 
family [201] have been shown to methylate arginine. H3K27me3 is catalyzed by the EZH2 subunit 
of the Polycomb repressive complex 2 (PRC2) [202]. Histone acetylation is catalyzed by histone 
acetyltransferases (HATs) [203-205], and acetyl groups are removed by histone deacetylases 
(HDACs) [206-208]. These enzymes can be targeted HDAC inhibitors such as valproic acid and 
hydroxamic acids derivatives [209]. 
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Cytosine methylation: Methylation of cytosines in the fifth position (5-methylcytosine, 5-
mC) is an epigenetic modification. The majority of the genome has a low cytosine/guanine 
content, and these cytosines usually are methylated, including transposons and other repeated 
elements. The cytosine nucleotide followed by the guanine nucleotide is expressed as “CpG”. 
CpGs often spontaneously undergo deamination and become thymine (CpT), resulting in 
underrepresentation of CpG [29]. Cytosine-rich regions are organized into CpG islands (CGIs) in 
the genome [210, 211]; these are short regions, about 300-3,000 bp, characterized by high 
cytosine content ( > 60%) [212, 213].  
These CGIs are enriched on gene promoter regions, and cytosines in CGIs usually are 
unmethylated and the methylation of promoters negatively correlates with transcript levels. There 
are two basic models for promoter hypermethylation-induced transcriptional silencing: DNA 
methylation can repress transcription directly by blocking transcriptional activators from binding to 
cognate DNA sequences, and methyl binding proteins recognize methylated DNA and recruit co-
repressors to silence gene expression directly. Genome-wide studies have also indicated that 
methylation of regions adjacent to CGIs, known as CpG shore regions, play a key role in diverse 
biological processes [214]. While the functional effect of gene body methylation has been 
debated, it has been shown that regulation of splicing through binding of CTCF (which is sensitive 
to cytosine methylation levels) results in pausing of RNA polymerase II [215-218]. It may also 
enhance transcription through inhibition of initiation of cryptic intragenic transcription [219-221].  
Cytosine methylation levels are usually the highest in fully differentiated cells; however, 
cytosine methylation is erased after fertilization, with only a handful of imprinted regions 
remaining methylated in zygotes [222-224]. During cell-type-specific differentiation, cytosine 
methylation is established by DNA methyltransferases (DNMTs) [225-229]. Dnmt1 is responsible 
for maintaining the established DNA methylation levels during cell division. Homozygous Dnmt1 
embryos are stunted, delayed in development, and do not survive past midgestation [225]. 
Dnmt3a and Dnm3b participate in de novo DNA methylation of unmethylated cytosines and 
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appear to methylate different genomic DNA regions in vivo. Dnmt3a actively methylates naked 
DNA and open nucleosomal DNA [230], while Dnm3b is specifically required for methylation of 
centromeric minor satellite repeats. It has been shown Dnmt3a and Dnmt3b double-mutant mice 
have severe growth defects and do not survive over 4 weeks after birth. While Dnmt3a mutant 
mice develop to term, there is no viable Dnm3b knockout and severe developmental defect at 
later stages of development is found [225, 226, 231-234]. Mutations of human DNMT3B are 
found in immunodeficiency, centromeric instability, and facial anomalies syndrome, a 
developmental defect characterized by hypomethylation of pericentromeric repeats [235, 236].  
In addition to cytosine methylation, the TET (Ten-Eleven-Translocation) enzymes are 
known to oxidize 5-mC to 5-hydroxymethylcytosine (5-hmC), adding a hydroxyl group to the 
methylation of cytosines at C5 position. 5-hmC was identified as having the ability to regulate 
gene expression in coordination with transcription factors [237]. When hydroxylmethylation is 
disrupted, it can result in disordered cell function, for instance, myeloid cancers [238-240]. 
1.4.5. Methods to study the epigenome 
Analyzing condition-relevant cell types is critical to understand the role of epigenetics to 
disease development (e.g. analysis of renal epithelial cells to understand kidney disease). 
Because the cell type is the key determinant of the epigenome, it is unlikely that much 
mechanistic understanding would be gained by analyzing cells that are not functionally relevant to 
disease development. Cytosine methylation is one of the most stable epigenetic marks, it can be 
studied even in archived samples because genomic DNA is stable [241-243]. 
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DNA Methylation: There are three major approaches to studying cytosine methylation, 
based on restriction enzyme digestion, affinity enrichment, and sodium bisulfite conversion. Each 
method has its strengths and caveats. Currently, all of these methods are available for both 
locus-specific and genome-wide studies when coupled with whole-genome-covering microarrays 
or sequencing technologies. 
The restriction enzyme digestion method is based on isoschizomer enzymes that 
recognize the same nucleotides but differentially digest DNA based on cytosine methylation 
status. The most frequently used isoschizomers for DNA methylation studies are HpaII and MspI, 
which recognize the same sequences but digest differently according to the methylation levels 
[244]. MspI is methylation-insensitive whereas Hpall is sensitive to methylation level. The 
methylation-insensitive enzymes are not able to cleave the methylated-cytosine residues, leaving 
methylated DNA intact. By comparing the fragments after restriction-enzyme treatments, site-
specific methylation differences can be determined (Figure 1-4A). The digested DNA can be 
subjected either to polymerase chain reaction (PCR) for locus-specific study, or to either 
microarray or sequencing for genome-wide screening.  
SmaI and its neoschizomer XmaI is another favored enzyme pair. Xmal and Smal both 
recognize the sequence CCCGGG, but they digest it at different sites. Smal is sensitive to 
cytosine methylation and is blocked by CG methylation, leaving a blunt end 5’-GGG. Xmal is 
methylation-insensitive enzyme that cleaves at sites with methylated CGs. Xmal leaves 5’-CCGG 
overhangs (Figure 1-4B). By comparing the two enzymes or use the restriction enzymes in serial, 
we can detect the differentially methylated regions [245-247].  
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The advantage of restriction enzyme digestion is its sensitivity to hypomethylated regions 
(e.g., CGIs). The drawback of this method is that the coverage and resolution is limited to regions 
that restriction enzymes recognize. One of the most commonly used restriction enzymes methods 
is HpaII tiny fragment enrichment by ligation-mediated PCR assay, developed by Suzuki et al 
[248, 249] and Thompson et al [250].  
Affinity enrichment methods use antibodies against m5C, or methyl group binding protein 
domains (MBD) that target m5C, such as MeCP2 or MBC. Five proteins with mCpG-binding 
motifs have been identified in the MBD family: MBD1, MBD2, MBD3, MBD4, and MeCP2 [251]. 
To capture m5C with antibodies and proteins, the genomic DNA is randomly sheared into small 
fragments by sonication. The fragments then subject to immunoprecipitation with antibodies 
targeting methylated cytosines in DNA (MeDIP) [252, 253]. The advantage of the MeDIP method 
is a true genome-wide coverage, because it is not limited by restriction enzyme sites. However, 
Figure 1-3| Schematic diagram of the restriction enzyme based method to identify 
differentially methylated regions. 
(A) MspI and HpaII digestion. HpaII is methylation-sensitive enzyme and MspI is methylation-
insensitive enzyme. Comparing the fragmentation of the enzyme digestion results, we can 
discover the differentially methylated regions. (B) methylated DNA and reduction of genome 
complexity were achieved by serial digestion with SmaI (methylation sensitive) and XmaI 
(methylation insensitive) restriction enzymes. Both (A) and (B) methods are suitable for whole 
genome analysis using microarray or sequencing platform. 
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the limited resolution of MeDIP is a key disadvantage. The binding of the antibody is determined 
by the cumulative methylation level of a region, and the resolution is limited by the degree of 
fragmentation from the sonication process.  
Determination of cytosine methylation by sodium bisulfite conversion is an unbiased and 
sensitive method, and is currently the “gold standard” for determining cytosine methylation [254-
257]. The method is based on the principle that unmethylated cytosines will be converted to uracil 
after bisulfite treatment, but methylated cytosines will not. Fragments can later be subjected 
either to cloning and sequencing or to mass spectrometry (e.g. the Sequenom EpiTYPER-type 
equipment, Sequenom, San Diego, CA) to interrogate locus-specific cytosine methylation. 
Genome-wide quantification of bisulfite-converted cytosines can be performed by either 
microarray- or sequencing-based platforms. The Infinium HumanMethylation450 BeadChip arrays 
(bisulfate conversion-based assays, Illumina, San Diego, CA) gained popularity as an easy and 
cost-effective method for methylation analysis. These arrays appear to perform quite well for 
epigenome-wide association studies. One key disadvantage is that they only analyze the 
methylation of 480,000 preselected loci, representing less than 1% of the whole genome. The 
reduced representation bisulfite sequencing is another bisulfite-conversion-based method that 
combines restriction enzyme-based size selection followed by next-generation sequencing. This 
method provides excellent coverage for CGI and promoter regions. Genome-wide bisulfite 
sequencing provides the best and highest resolution method to examine cytosine methylation 
status. The main drawback of this method is the current cost associated with whole-genome 
sequencing and data analysis. 
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Chromatin Immunoprecipitation Chromatin immunoprecipitation (ChIP), followed by 
either microarrays or next-generation sequencing (ChIP-chip/ChIP-Seq), is the most frequently 
used method to map transcription factor binding and histone modifications. Here, genomic DNA 
and proteins in either live cells or fresh tissues are cross-linked with formaldehyde, and the 
chromatin is fragmented into 200 base pair size. The sheared DNA/protein complex is then 
subjected to immunoprecipitation with an antibody against the selected transcription factor or 
histone tail modification. Once the genomic DNA is reverse cross-linked and released from the 
protein complex, it can be analyzed using quantitative PCR, microarrays, or sequencing.  
Although ChIP has revolutionized our understanding of the epigenome, the method is not 
without limitations. First, the method does not provide an epigenetic map with base pair 
resolution, because the resolution is limited by the size of the sheared chromatin. To circumvent 
this issue, an enzyme digestion-based method, the exo-ChIP, was developed [258]. The key 
limitation of the ChIP-seq relates mainly to the specificity of the antibodies used for the studies. 
To address this issue, several antibody validation databases were created to evaluate antibody 
quality [259-261]. 
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Next-generation sequencing platforms and data analysis: For genome-wide bisulfite 
sequencing, high genome coverage (usually at least 30X) and long reads are needed. 
Sometimes, 500-to-600 bp paired-end sequencing (e.g. MiSeqV2 System generates paired 250 
bp or MiSeqV3 that generates paired 300 bp reads) is used [262]. For ChIP-seq, generally 100-
bp single-end sequencing is used. ChIP-seq analysis begins by aligning each read to the 
reference genome and then determining the number of reads that aligned within each genomic 
region. A frequently used aligner is BWA. After reads are aligned, we can define protein binding 
sites using sequence reads enrichment in the genome, which is termed peak calling. Several 
peak calling algorithms are available including SPP [263], PeakSeq [264], and MACS [265], 
which were used in the ENCODE consortium [266]. Other available tools include SICER [267] 
and Genome-Wide Event Finding and Motif Discovery (GEM) [268]. Most of the methods target 
peaks that are around 150-300 bp, e.g. MACS and PeakSeq, whereas SICER identifies rather 
diffused histone marks that can span kilobases to megabases of the genome. Another special 
feature of these method is that GEM improves the resolution of peaks by combining peak calling 
and motif analysis. 
Because the accessibility of each genomic region is slightly different, an enrichment 
score is developed to show the enrichment fraction normalized to input DNA (that is, sonicated 
DNA without antibody enrichment). Both the degree of enrichment and the size of the region that 
is marked by an individual histone mark are important, because several different modifications 
can be present on an individual region. To address this challenge, several algorithms have been 
developed using statistical methods that incorporate histone mark information to identify 
functional elements from high-throughput genomic data sets. Ernst and Kellis et al [269] 
developed a method that is based on the hidden Markov Model, which can be used to generate 
gene regulatory region annotation based on a panel of histone ChIP-seq experiments performed 
on the same sample. The method takes into consideration the presence of multiple different 
histone marks and their reference sequence-based location. This method is very valuable for 
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comparing multiple different histone marks, either between different cell types, or within the same 
cell type but expressing different phenotypic characteristics, to highlight key similarities and 
differences in datasets.  
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CHAPTER 2: Genetic-variation-driven gene-expression changes 
highlight genes with important functions for kidney disease 
2.1. Abstract 
Chronic kidney disease (CKD) affects close to 10% of the US population and is 
associated with a 3- to 5-fold increase in risk of death. Genome-wide association studies 
(GWASs) have identified sequence variants, localized to non-coding genomic regions, associated 
with kidney function. Despite these robust observations, the mechanism by which variants lead to 
CKD remains a critical unanswered question. Expression quantitative trait loci (eQTL) analysis is 
a method to identify genetic variation associated with gene expression changes in specific tissue 
types. We hypothesized that an integrative analysis combining CKD GWAS and kidney eQTL 
results can identify candidate genes for mechanistic and causal studies. 
We performed eQTL analysis by correlating genotype with RNAseq-based gene 
expression levels in 96 human kidney samples. Applying stringent statistical criteria, we identified 
1,886 genes (eGenes) associated with sequence variants. Using direct overlap and Bayesian 
methods, we identified new potential target genes for CKD. With respect to one of the target 
genes, Lysosomal Beta A Mannosidase (MANBA), we observed that SNPs associated with 
MANBA expression in the kidney showed statistically significant colocalization with SNPs 
identified in CKD GWAS studies. The results indicate that MANBA is a likely causative factor in 
CKD. The expression of MANBA was significantly lower in kidneys of subjects with risk alleles. 
Suppressing MANBA expression in zebrafish resulted in pericardial edema, a phenotype typically 
induced by kidney dysfunction.  
Our analysis shows that gene-expression changes driven by genetic variation in the 
kidney can highlight potential new target genes for CKD development. 
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2.2. Introduction 
The key function of the human kidney is to remove waste from the body.  The kidney 
filters more than 180 liters of plasma every day and selectively reabsorbs or secretes specific 
electrolytes. The kidney excretes most of the endogenous and exogenous waste products that 
the body can modify into hydrophilic compounds. Ten percent of the body’s basal energy 
requirement is used by the kidney to perform its transport function [5, 270]. Chronic kidney 
disease (CKD) is characterized by at least a 40% decrease in the filtering function or abnormal 
leakiness to albumin. CKD is a common condition affecting close to 20 million people in the US 
and 10% of the population worldwide [6, 271]. Impaired kidney function is associated with a 3- to 
5-fold increase in risk of death [272-274]. 
CKD is a gene-environment disease, and diabetes and hypertension are responsible for 
more than 75% of the CKD cases in the US [275, 276]. The genetic underpinning of CKD has 
been examined by genotyping and phenotyping large numbers of subjects with CKD and 
conducting GWAS studies. In most GWAS studies, creatinine-based estimates of kidney function 
(eGFRcrea) have been used to define kidney disease. Our review of the literature identified 110 
loci that exhibited significant genome-wide association with CKD status. The association between 
genetic variants and disease has been replicated by several studies, indicating the robustness of 
the relationship.  
Despite the remarkable progress of the GWAS experiments, these results have not 
translated into improved understanding of the mechanisms of CKD development. One critical 
bottleneck is that more than 90% of the CKD-associated SNPs are localized to non-coding 
genomic regions [34]. It is not clear, though, which genes and which cell types are affected by the 
genetic variants. Data from other complex-trait studies indicate that disease-causing genetic 
variants are localized to regulatory regions in disease-relevant cell types, altering transcription 
factor binding and downstream quantitative expression of target genes [69]. 
Most GWAS studies have proposed the nearest gene as the causal gene for disease 
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development; however, mechanistic research indicates that the nearest gene is often not causal, 
and identification of GWAS targets remains difficult [277, 278]. The expression quantitative trait 
loci (eQTL) method has been developed to associate genetic variation with gene expression 
changes. The method requires genotype- and tissue-specific gene-expression data from large 
numbers of healthy individuals, and controlled complex computational methods, to identify 
genotype-driven gene expression changes. Several tissue types have been difficult to collect in 
large enough numbers to perform eQTL analysis. The largest eQTL datasets have therefore been 
generated from easily accessible cell types, for example blood [97]. The Genotype Tissue 
Expression Project (GTEx) Consortium was established to circumvent tissue-procurement 
problems, and has been successful in creating a large number of eQTL datasets.[92] 
Unfortunately, the number of kidney samples in GTEx (n=26) is limited due to allocation and 
organ transplantation; hence GTEx has not published kidney-specific eQTL maps. 
The aim of the current study was to generate a kidney-specific eQTL dataset and 
integrate this information with CKD-associated GWAS variants, in order to identify target genes 
for chronic kidney disease and thereby better understand kidney function and disease 
development.  
 
2.3. Results 
2.3.1 eQTL analysis of human kidney tissues 
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We obtained genotype and gene expression data for 99 normal European descent 
human kidney cortical samples. Genotype data was obtained from Genome-Wide Human SNP 
Array 6.0 and expression data by RNA sequencing. We excluded samples that did not pass 
quality control (QC), and to avoid detecting genetic variations that are caused by population 
genetic structure differences, we further removed samples using principal component analysis 
(PCA) (Figure 2-1) [279-281]. There were 96 individual samples that passed QC and were used 
for downstream analysis (see Methods). These samples were phased and imputed from the 
1,000 Genome Phase 3 haplotype CEU reference panel using SHAPEIT and IMPUTE2 [62, 282]. 
Gene expression data were normalized using quantile normalization followed by inverse normal 
transformation. We then added sex and age as covariables for probabilistic estimation of 
expression residuals (PEER) before the final transformation of the residuals (see Methods).  
We determined the association between 5.1 million genetic variants and expression of 
17,388 genes using Matrix eQTL (Figure 2-2) [283]. The analysis was limited to cis-eQTLs whose 
SNPs and gene pairs were within 1MB distance. We followed the protocol described in GTEx to 
Figure 2-1 | PCA plot of kidney samples against 1000 genomes reference genome. 
PCA analysis of kidney samples against the 1000 Genomes AFR, AMR, EAS, EUR and SAS 
populations. Color code is provided as shown in the right of the panel. Subjects from TCGA 
study are shown in pink. One sample labeled with red arrow was removed after PCA. 
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correct for multiple testing and establish significance [92]. In summary, we obtained permutation-
adjusted p-values for each gene using FASTQTL [284], which yielded the most significant gene-
SNP pairs. After deriving the empirical p-value from this analysis, we calculated the q-value using 
the Storey method [285], with a significance threshold of less than or equal to 0.05. This method 
identified 1,886 eGenes and 124,612 eQTL SNPs (eSNPs) (Appendix 2). In summary, we have 
generated human kidney eQTL data from 96 CEU samples.  
2.3.2 Validation and replication of kidney cis-eQTL signals  
Figure 2-2 | Cis-eQTL analysis of human kidney genome. 
(A) Flowchart of eQTL analysis (B) Global significance of eQTL SNPs across the genome. The y-
axis shows –log10 p-value; the significance threshold used in our analysis is determined by the 
corrected permutation test p-value. 
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 To evaluate the kidney eQTL signals, we first compared the number of eGenes identified 
by our analysis to 32 other tissue samples published in GTEx (v6). The analysis was limited to 
Figure 2-3 | Positive correlation between sample number and identified eGenes. 
The number of eGenes discovered is strongly correlated positively to the number of samples 
used for the analyses. Tissues from GTEx (v6) were used as comparison, with the selection 
criteria that each tissue type has to have more than 90 samples. The number of eGenes ranged 
from 1628 in liver to 9937 in thyroid. Kidney sample (n=96) is shown in red. 
Significant eQTL SNP-gene pairs are overlapped between kidney and the 32 samples from 
GTEx (v6). We also observed a strong positive correlation of sample number and SNP-gene pair 
replication. The x-axis shows the sample number of each tissue type; the y-axis is the number of 
eSNP-eGene pair overlapped between GTEx samples with kidney eQTL. 
 
Figure 2-4 | Positive correlation between sample number and replicated significant SNP-
eGene pairs. 
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tissue samples where more than 90 samples were analyzed. The number of significant eGenes 
(n=1,886) in the kidney eQTL followed the expected linear relation between sample size and 
number of detected eGenes observed by GTEx (Figure 2-3). We also surveyed the overlap of 
eSNP-eGene association between kidney eQTL in the 32 tissue types in GTEx (v6). Consistent 
with previous studies, larger sample size increased the power of association detection, and we 
observed higher eQTL eSNP-eGene pair overlap among samples at larger sample sizes (Figure 
2-4).  
Next, given that eSNPs influence gene expression, we analyzed whether eSNPs are 
enriched on regulatory regions. We plotted the significance of association between eSNPs and 
their distance to transcription start sites (TSSs). We found that the strength of association was 
greater around the TSSs (Figure 2-5A), indicating that eSNPs were enriched around transcription 
start sites, likely promoter regions.  
To establish that the eSNPs were in fact enriched on regulatory regions, we used histone 
tail modification-based chromatin immunoprecipitation sequencing (ChIP-seq) to identify kidney-
Figure 2-5 | Significant SNPs in the eQTL are enriched at regulatory regions. 
(A) Density plot of eSNPs and their distance relative to TSS. (B) eSNPs overlap with 6 different 
histone marks in human kidney proximal tubule epithelial cells, compared with the 1000 null sets 
of variants matched for number, distance to TSS and frequency. The vertical line represents the 
95% confidence interval. Histone marks with significance level of p-value < 1.0E-2 are 
highlighted with red asterisks. (C) eSNP enrichment in ENCODE TFBSs. Odds ratios of eSNPs 
are shown in y-axis and the vertical line represents 95% confidence interval. We marked the 
TFBSs reaching significance level p < 1.0E-2 with red asterisks. Control SNPs were the 1000 
null sets of variants that are matched to eSNPs for number, distance to TSS and allele 
frequency. 
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specific regulatory regions. We performed this analysis using different histone tail mark-specific 
antibodies and human kidney proximal tubule cells (HKC8) [166]. We overlapped eQTL SNPs 
with each histone mark, quantifying the enrichment ratio by comparing it with 1,000 randomly 
generated SNP sets that were matched for frequency and distance. To avoid enrichment bias, we 
removed variants in the same linkage disequilibrium (LD) (see Methods). Kidney eQTL SNPs 
were statistically significantly enriched (~4-fold) on active promoters, as they showed highest 
enrichment with active promoter marks H3K4me2 and H3K4me3 (p-value < 0.01). There was no 
statistically significant enrichment for repressed promoter and gene-body-specific histone marks 
(Figure 2-5B). These studies indicate that kidney eQTL SNPs are enriched on promoter/enhancer 
regions in the kidney.   
Another feature of regulatory regions is that they are enriched for transcription factor 
binding sites. We next examined the overlap of eSNPs with the transcription factor binding ChIP-
seq data from ENCODE [186, 286, 287]. We found that eSNPs were statistically significantly 
enriched for transcription factor binding sites. Specifically, we found enrichment for CBX3, 
HDAC1, KDM5b, NRF1, ZEB1, IRF1, SIX5, and ZEB1 binding compared to 1,000 randomly 
generated SNP sets that were matched for frequency and distance (Figure 2-5C). Many of these 
transcription factors have been shown to be important in kidney development or kidney disease 
[288-290]. An example of a kidney-specific eQTL is shown in Figure 2-6A-B, where rs946213 
variant influences the expression of RRP15. The SNP is located at a promoter and the variant 
interrupted the GATA5 binding site.  
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In summary, kidney eQTLs were enriched on kidney-specific regulatory regions, 
indicating the robustness of the approach. Our results indicate enrichment of the eSNPs on 
kidney-specific active promoter regions and transcription factor binding areas. 
2.3.3 eGenes are enriched for metabolism-associated genes  
Figure 2-6 | An example of significant SNPs in the eQTL that is enriched at regulatory 
regions. 
(A) One example region at chr1:218.45-218.514 Mb, SNP rs946213, affects expression levels 
of RRP15, and the gene and the SNP are located in histone marks including H3K4me1, 
H3K4me3 and H3K27ac. SNP r61823376 also disrupts transcription factor GATA5. (B) RRP15 
expression level is significantly lower in samples with rs946213 minor alleles (p-value = 7.81E-
15). 
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According to GTEx, large numbers of eQTLs are conserved between different organs 
[92]. After overlapping kidney eGenes with 9 different tissue types in GTEx (v4) eGenes, we 
found 847 eGenes unique to kidney eQTL, indicating that our analysis identified both shared and 
unique eQTLs. To understand the functional role of the eGenes, and therefore the eQTL 
regulatory mechanism, we performed gene ontology (GO) analysis using all 1,886 eGenes and 
the Database for Annotation, Visualization and Integrated Discovery method (DAVID v6.7), which 
includes eGene-enriched pathways in the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
[291]. As shown in Figure 2-7A, we found that the most significantly enriched pathway was 
related to metabolism, specifically drug and xenobiotic metabolism (p-value = 2.30E-06), which is 
a key function of the kidney.  
To further understand the xenobiotic-metabolic eGene properties, we performed network 
analyses using Ingenuity Pathway Analysis (IPA). IPA highlights the xenobiotic pathway (p-value 
= 1.57E-23) in Figure 2-7B. In summary, many of the kidney eGenes show enrichment for drug, 
Figure 2-7 | Network of eGenes. 
(A) The most significant eGene pathway is enriched in metabolic pathways and xenobiotic and 
drug metabolism. The KEGG pathways displayed here are those below the Benjamini-Hochberg 
corrected p-value of 5.0E-2. (B) IPA analysis of eGenes in the pathway related to metabolism of 
xenobiotics. Genes presented in the significant eGene list are in orange, and the rest of the 
genes in the network were supplied algorithmically. Genes enclosed in the box are kidney-
specific eGenes. 
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xenobiotic metabolism, and pharmacogenomics, which is highly consistent with the function of the 
kidney and could be related to the higher expression these genes in the kidney (Figure 2-8).  
2.3.4 Kidney eQTL highlights the genetics of disease traits  
A critical goal of eQTL analysis is to provide a framework for biological interpretation of 
disease-related variants. To evaluate the relevance of the eQTLs identified in disease-mapping 
studies, we tested kidney eQTL SNPs with disease-associated SNPs using the National Human 
Genome Research Institute (NHGRI) catalog (www.ebi.ac.uk/gwas, accessed 9/30/2015) [292]. 
We analyzed statistical enrichment for GWAS SNPs in our kidney eQTL database (see Methods). 
We found that kidney-specific eQTL SNPs are enriched for CKD-associated traits (Figure 2-9). 
When compared to other traits (digestive, nervous, immune system diseases, cardiovascular, 
body measurement, biological processes, and other diseases) we found a significantly greater 
overlap between kidney eSNPs and polymorphisms that are associated with kidney function [35, 
36, 293, 294]. These results indicate that genetic variants associated with kidney function and 
CKD are enriched in our eQTL studies and likely drive gene expression changes in the kidney.  
Figure 2-8 | Density distributions of gene expression of eGenes and all genes in kidney 
samples. 
Gene expression distributions are shown for both eGenes and all genes. A shift toward higher 
expression of eGenes can be seen with the overlap of the translucent plots. All genes are 
shown in light red and eGenes are in light blue. 
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2.3.5 Defining the genetic network underlying CKD 
A key objective of our study was to identify potential target genes for CKD-associated 
GWAS variants. We manually curated a list of SNPs that both passed genome wide significance 
Figure 2-10 | Integrative analysis of GWAS and eQTL SNPs. 
(A) We used eSNPs that are also present in CKD-associated GWAS as a means to identify 
target genes that affect kidney disease. (B) Boxplot of rs1719246 and SPATA5L1, rs6429746 is 
within the LD block with rs2467853, which is one of the CKD-associated GWAS-identified SNPs 
(D'= 0.95; r2 = 0.89). 
Figure 2-9 | Disease trait GWAS Enrichment analysis. 
SNPs associated with different traits were taken from National Human Genome Research 
Institute (NHGRI) database, with SNPs categorized based on disease ontology. Enrichment 
was calculated using Fisher's exact test; the significance is shown in the y-axis with -log10 p-
value. 
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and were associated with kidney disease traits. To acquire independent loci, we removed any 
SNPs having r2 ≥ 0.2. In total, we analyzed 110 leading SNPs and 2,357 tagging SNPs with r2 ≥ 
0.8. We performed a direct overlap between CKD-associated GWAS SNPs and eQTL SNPs 
(Figure 2-10).  
Overlapping SNPs were identified between the two datasets. These SNPs passed 
genome-wide significance both in GWAS and eQTL studies.  They mapped to seven loci (eight 
genes) and regulated the expression of CST9, SPATA5L1, LOC654433, ACCS, CFHR1, 
ALMS1P, PGAP3 and TPRKB (Table 2-1). 
Table 2-1 | SNPs identified in human kidney eQTL that are in tight LD with CKD 
GWAS SNPs 
Trait GWAS 
P-
value 
CKD 
GWAS 
SNP 
CKD GWAS 
suggested 
target Genes 
eGene 
identified 
eQTL 
eSNP 
Best P-
value 
eSNP to target gene TSS 
BUN 3.30E-
10 
rs111231
70 
PAX8 LOC65443
3 
2.67E-07 9,927 bp upstream of TSS 
CKD 1.05E-
42 
rs246785
3 
GATM/SPATA5
L1 
SPATA5L1 3.75E-08 41,152 bp upstream of TSS 
eGFRcr
ea 
4.50E-
14 
rs13538 ALMS1/NAT8 ALMS1P 2.63E-06 25,029 bp upstream of TSS 
       TPRKB 8.24E-07 115,584 bp downstream of 
TSS 
eGFRcr
ea 
9.00E-
13 
rs110789
03 
CDK12 PGAP3 1.28E-10 339,337 bp downstream of 
TSS 
eGFRcy
s 
2.20E-
88 
rs130383
05 
NAPB, CSTL1,  
CST11, CST8,  
CST9L, CST9,  
CST3, CST4,  
CST1, CST2, 
CST5  
CST9 2.68E-09 9,027 bp upstream of TSS 
IgA-NP 3.93E-
09 
rs207403
8 
ACCS ACCS 3.01E-14 510 bp downstream of TSS 
IgA-NP 2.96E-
10 
rs667760
4 
CFHR1,3 CFHR1 6.93E-07 77,945 bp upstream of TSS 
 
The direct overlap method has a few limitations. First, eQTL and GWAS variants were 
not genotyped on the same platform, and a large number of variants were missing in the eQTL 
genotypes. Second, the method is very stringent, as it requires independent genome-wide 
significance for the SNPs in both studies, even though the GWAS and eQTL studies can gain 
significance from each other as they are independent methods.  
To address the latter issue, we also implemented a Bayesian method (coloc [295, 296]) 
to formally test the hypothesis of association of a given region with eQTL and GWAS signals. Due 
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to the nature of the analyses, we could only import one study from GWAS analyses instead of 
using our curated list with a multiple cohort of studies.  As input to coloc, we used the largest 
GWAS of the kidney function measure eGFR from the CKDGen Consortium with the best 
statistical power, and its known summary statistics and sample sizes [69]. The five hypotheses 
used in the coloc analyses were: H0: No association with either trait (trait 1 for eGFR GWAS and 
trait 2 for eQTL associations or vice versa); H1: Association with trait 1, not with trait 2; H2: 
Association with trait 2, not with trait 1; H3: Association with trait 1 and trait 2, two independent 
SNPs; H4: Association with trait 1 and trait 2, one shared SNP. As sufficient support for significant 
results, we set PP4 > 0.8 and PP4/PP3 > 5 (posterior probability from H3 and H4) as criteria 
[297]. Here we used only SNPs that are associated with the eGFRcrea trait in the GWAS studies. 
As expected, this method identified SNPs that passed genome-wide significance in both 
methods, including Post-GPI Attachment To Proteins 3 (PGAP3), Spermatogenesis Associated 5 
Like 1 (SPATA5L1), and Alstrom Syndrome 1 Pseudogene (ALMS1P). Furthermore, several 
additional potential target genes were identified, including PIGU, METTL10, MANBA, and others 
(Table 2-2). 
PGAP3 encodes phospholipase for the glycolipid complex (glycosylphosphatidylinositol, 
or GPI) in the Golgi apparatus. The modification is crucial for linking GPI-anchored proteins to 
lipid rafts, which plays an important role in protein sorting and trafficking. One of the major 
phenotypes of PGAP3 knockout mice is that they present with progressive enlarged renal 
glomeruli with deposition of immune complexes and matrix expansion upon aging.[298] 
Furthermore, humans with PGAP3 loss-of-function mutations present with neurological and renal 
phenotypes [299, 300]. These experimental observations nicely validate our computational 
methods.  
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2.3.6 Integrative analysis identifies MANBA as a potential gene for CKD  
To prioritize the validation of target genes, we performed network analysis for all eGenes 
using IPA. IPA highlights the metabolic pathway with a score of 38 (the negative log p-value of 
the odds ratio). MANBA was the only gene predicted in coloc that is presented in the pathway 
(Figure 2-11).  
The GWAS study revealed a significant association between chromosome 4 SNPs and 
Table 2-2 | Significant genes identified through Coloc that are associated to both CKD 
GWAS- and human kidney-identified SNPs 
Gene PP_H3 PP_H4 H4/H3 
1. PGAP3 0.012715756 0.985344385 77.49 
2. SPATA5L1 0.015059344 0.979123189 65.02 
3. METTL10 0.009878945 0.978529109 99.05 
4. PIGU 0.040348343 0.955231251 23.67 
5. KNG1 0.013444728 0.955009245 71.03 
6. MANBA 0.063418013 0.913297935 14.40 
7. ALMS1P 0.002501869 0.887791453 354.85 
8. C9 0.004801323 0.884400778 184.20 
9. WHAMM 0.004698951 0.882157986 187.74 
Figure 2-11 | Integrative analysis of GWAS and eQTL SNPs. 
(A) We used eSNPs that are also present in CKD-associated GWAS as a means to identify 
target genes that affect kidney disease. (B) Boxplot of rs1719246 and SPATA5L1, rs6429746 is 
within the LD block with rs2467853, which is one of the CKD-associated GWAS-identified SNPs 
(D'= 0.95; r2 = 0.89). 
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eGFR. While the genetic variants were located in the non-coding genomic regions, the proposed 
likely causal gene for kidney function in the GWAS study was listed as NFKB1. On the contrary, 
our analysis indicates MANBA is a potential target gene for kidney-function associated GWAS 
variants. We examined the association of gene expression based on the GWAS variants, and 
found that while MANBA shows statistically significant changes based on the genotype, 
expression of nearby genes, including NFKB1, was unaffected.  
We found that the SNPs associated with kidney function also influenced the expression 
of MANBA. While the top GWAS SNP was not present in our eQTL database, we observed that 
Figure 2-12 | Genetic and epigenetic annotation of MANBA-locus SNPs. 
The lower-left part of the square is the analysis of LD between all of the chromosome 4:103.4-
103.8Mb region using Haploview version 4.2 (http://www.broad.mit.edu/mpg/haploview). The 
strength of the LD is shown in the grey gradient as indicated in the figure. Pair-wise D' values 
were calculated and plotted using Haploview v4.1. Dashed lines indicate the annotated genes in 
the locus. The upper-right corner of the square shows chromosome conformation capture (Hi-C) 
interactions contact probabilities in a human lymphoblastoid cell line (GM12878). The plot 
shows the 200 kb topologically associating domain at 1kb resolution. Locations of both CKD and 
eQTL SNPs are labeled. (B) The zoom-in locus of MANBA region at chr4:103.5-103.64 Mb. 
CKD GWAS SNP, MANBA-associated best eSNP, and the overlapped SNP between two 
datasets are labeled on the plot. (C) The genome browser display of the MANBA region. Tracks 
from top to bottom are: UCSC gene annotation; H3K4me1 and H3K27ac overlays of 9 cell lines 
from ENCODE; human kidney histone mark H3K4me1, H3K4me3, and H3K27ac from 
Epigenome RoadMap; and ENCODE chromatin states (ChromHMM) showing the regulatory 
properties of the sequence. (D) Sequence-predicted TF motifs were shown in the bottom for 
rs227361 (overlapped SNP) and rs170563 (eSNP of MANBA). SNP rs227361 disrupts 
transcription factor IRF2 motif and rs170563 disrupts FOXP2 motif. 
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the eGFR GWAS SNPs and eQTL variants were in strong LD. Figure 2-12 shows the LD 
structure of the human MANBA region. The top eGFR (rs228611) and eQTL (rs227361) SNPs in 
the chr4: 103.5 Mb-103.6 Mb region were within the same LD block (r2=0.88, D’=0.95). Upon 
examining the interaction by extended chromosome conformation capture (Hi-C) in the human 
lymphoblastoid cell line (GM12878), we found that the eQTL and GWAS regions were likely 
interacting with each other, which could explain our results.  
Figure 2-13 | Locuszoom plots in MANBA region at chr4:103.4-103.8Mb. 
(A) CKDGen Phase III GWAS SNPs and the corresponding -log10 p-value. (B)-(D) are eQTL 
association of MANBA in kidney, whole blood, and transformed fibroblasts in GTEx (v6). 
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Next, we examined whether the eQTL signal can be replicated in other organs. Upon 
examining the GTEx database we found that transformed fibroblasts showed a similar association 
between genotype and gene expression as we observed in the kidney (Figure 2-13). 
Unfortunately, the GTEx Browser does not contain kidney eQTL, which prevented us from 
performing the comparison. However, only the pattern of the transformed fibroblasts eQTL signal 
generated by GTEX closely resembled the kidney eQTL signal.  
Figure 2-14 | Genetic and epigenetic annotation of MANBA-locus SNPs. 
(A) The zoom-in locus of MANBA region at chr4:103.5-103.64 Mb. CKD GWAS SNP, MANBA-
associated best eSNP, and the overlapped SNP between two datasets are labeled on the plot. 
(B) The genome browser display of the MANBA region. Tracks from top to bottom are: UCSC 
gene annotation; H3K4me1 and H3K27ac overlays of 9 cell lines from ENCODE; human 
kidney histone mark H3K4me1, H3K4me3, and H3K27ac from Epigenome RoadMap; and 
ENCODE chromatin states (ChromHMM) showing the regulatory properties of the sequence. 
(C) Sequence-predicted TF motifs were shown in the bottom for rs227361 (overlapped SNP) 
and rs170563 (eSNP of MANBA). SNP rs227361 disrupts transcription factor IRF2 motif and 
rs170563 disrupts FOXP2 motif. 
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To further identify the causal variant (region), we also analyzed histone ChIP-Seq-based 
regulatory annotation maps. Human-kidney-specific annotation maps indicated that the most 
enriched histone marks are H3K4me1 and H3K27ac (active enhancer), which overlapped with the 
eSNPs Figure 2-14A. Examining the ENCODE database, we confirmed that several cell types 
also showed H3K27ac enrichment of this region. There was no H3K27ac enrichment around the 
top GWAS variant in human kidneys or other ENCODE cells, although fibroblasts showed 
enrichment for the latent enhancer mark H3K4me1. The eSNP rs170563 was enriched for the 
H3K27ac histone mark and disrupted the FOXP2 transcription factor binding site, suggesting that 
rs170563 eSNP potentially has a regulatory function. Detailed examination of the MANBA locus is 
shown in Figure 2-14B-C. 
In summary, the observed eQTL signal overlapped with active enhancer regions both in 
the kidney and other organs, while the GWAS signal has no enrichment of the histone marks, 
suggesting that the causal variant is most likely in the region of eQTL-identified region and not in 
the peak GWAS region.  
2.3.7 Analysis of MANBA gene expression  
Next, we examined the gene expression of MANBA in different organs. Using the protein 
atlas [301] and Illumina Body Map (GSE30611), we found that the reproductive tract and the 
kidney both have intermediate expression of MANBA (not shown), and MANBA is expressed in 
lysosome of kidney tubule cells (Figure 2-15A).[302] Segment-specific expression data obtained 
from rat kidneys [303] indicate that MANBA is expressed in the long descending limb of the loop 
of Henle in the inner medulla, with the highest expression level in the inner medullary collecting 
duct segment.  
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Next, we examined the direction of regulation by the risk allele. We found that expression 
of MANBA was much lower (close to 50%) in healthy human kidney tissue samples obtained from 
subjects with risk alleles when compared to reference allele (Figure 2-15B).  
We also analyzed MANBA expression in patients with chronic kidney disease. We have 
examined MANBA expression analyzed by Affymetrix microarrays on 95 human kidney 
samples.[290] We found that MANBA expression is lower in patients with CKD and kidney fibrosis 
(Figure 2-15C). Similarly, expression of MANBA was lower in a mouse model of fibrosis induced 
by unilateral obstruction (unpublished data) fibrosis (Figure 2-15D). In summary, MANBA 
expression was lower in risk allele samples. 
2.3.8 Knockdown of Manba results in kidney defect in zebrafish 
Figure 2-15 | Gene expression analyses of MANBA. 
(A) Immunohistochemistry staining in human kidney tissues (Protein Atlas). (B) Boxplot 
showing association between rs170563 and MANBA. (C) Gene correlation with eGFR, the 
leading indicator of kidney function, using microarray and clinical parameters collected in a 
different independent cohort of 95 human kidneys. (D) Manba expression is significantly lower 
in mouse UUO model compare with sham (n=3 in each group). The statistical analysis results 
from DESeq are presented in the table under the plot. 
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As healthy subjects with risk alleles had lower MANBA expression, we wanted to 
understand the functional significance of lower MANBA expression. We conducted genetic 
knockdown experiments in zebrafish (Danio rerio). We used two different forms of morpholino 
oligonucleotides, translation blocking, and splice blocking. We confirmed the MANBA knockdown 
efficiency by quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis 
(Figure 2-17F). Zebrafish with MANBA knockdown presented with significantly increased 
pericardial edema and lethality. Pericardial edema is a commonly observed kidney defect 
phenotype in zebrafish (Figure 2-16A), as the fish is unable to excrete salt and water upon kidney 
dysfunction. Careful quantification of the phenotype is shown in Figure 2-17A, B. To confirm that 
the pericardial edema was caused by renal defect, we turned to Tg(enpep:GFP) zebrafish[304], 
which express GFP in pronephric ducts. GFP expression was reduced in the pronephros of 
MANBA knockdown embryos compared to controls. GFP expression was significantly reduced, 
and indeed often absent, in the Manba knockdown morphants (Figure 2-17C, D).  
Figure 2-16 | Kidney defect phenotype observed in zebrafish after knockdown MANBA. 
(A) Edema in zebrafish: Pericardial edema after gene knockdown is shown on the right panel; 
the control-injected zebrafish has no edema at 200 𝜇M concentration. (B) Edema rate of Nfkb1 
and Manba knocked-down zebrafish; p-values were calculated for each concentration group 
using Fisher's exact test. We tested the suggested target gene from GWAS study to confirm the 
eQTL analysis result. 
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Because heart developmental defects could also contribute to edema formation, we analyzed 
heart morphology on hematoxylin- and eosin-stained sections. From the histological analysis, we 
did not observe severe heart abnormalities in zebrafish with severe edema (Figure 2-17E), which 
indicates that reduced MANBA levels are likely associated with kidney function defect in the 
zebrafish model. Knockdown of Nfkb1, which was suggested as the causal gene by GWAS 
studies, did not develop kidney related phenotypes in zebrafish (Figure 2-16B). In summary, 
genetic knockdown of eQTL target gene MANBA, but not the proposed GWAS target NFKB1, 
was associated with kidney development defect in zebrafish. 
Figure 2-17 | Kidney defect phenotype observed in zebrafish after knockdown MANBA. 
(A) Edema in zebrafish: Pericardial edema after gene knockdown is shown on the right panel; the 
control-injected zebrafish has no edema at 200 𝜇M concentration. (B) Edema rate of Nfkb1 and 
Manba knocked-down zebrafish; p-values were calculated for each concentration group using 
Fisher's exact test. We tested the suggested target gene from GWAS study to confirm the eQTL 
analysis result. 
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2.4. Discussion and Conclusion 
Genetic variation has significant impact on gene expression regulation, downstream 
organ function, and phenotype development. Here we present the first comprehensive RNA 
sequencing-based gene expression analysis for genetically driven gene-expression changes in 
human kidney samples. While large-scale efforts are in progress to generate comprehensive 
eQTL analysis for the human body, kidney-specific maps have not been generated. Our project 
aims to fill that gap by generating kidney-specific maps. 
Our results indicate that while a large percentage of genotype-driven gene-expression 
variation is conserved between different tissue types, kidney-specific maps have highlighted 
variation in gene levels that play a key role in kidney function, indicating the critical need for 
tissue-specific maps. In prior work, an algorithm has been developed to impute expression levels 
for unavailable tissue types on the basis of eQTL. However, the sample size available today does 
not carry enough power to detect tissue-specific eQTLs [305]. 
We further found that kidney eSNPs showed tissue-specificity and are enriched on 
kidney-specific regulatory regions: promoters, enhancers and transcription factor binding sites. 
We used the kidney eSNPs we discovered to interpret disease-related variants discovered in the 
GWAS studies. We found four major loci where genome-wide significant eSNPs and eGFR-
associated GWAS SNPs directly overlapped. We also employed Bayesian methods to confirm 
that eSNPs and GWAS-associated SNPs are present at the same locus and contribute to both 
phenotypes and gene expression levels. This analysis highlighted several genes that are likely 
responsible for the association observed between genotype and kidney disease associated traits 
in large-scale GWAS. For example, Cystatin 9 (CST9), variants showed association with serum 
cystatin levels. Another example is PGAP3, the phospholipase that attaches GPI to proteins, 
which is another likely causal gene for CKD development.  
We have further focused our analysis on MANBA as a likely causal gene for genetic 
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variants on chromosome 4 shown to be associated with CKD. Variants that are associated with 
CKD traits also altered the expression of MANBA in human kidney samples. The risk genotype 
was associated with lower levels of MANBA levels in human kidney samples. Interestingly, this 
association can be recapitulated in the fibroblast cell line in the GTEx dataset, potentially 
indicating that the signal could come from fibroblasts. A similar direction on gene expression was 
observed in patients with kidney disease and mouse models with kidney fibrosis. We have used 
the zebrafish model to show that lower MANBA expression is causally related to kidney disease 
development. Morpholino knockdown of Manba resulted in pericardial edema formation, 
indicating the functional role of MANBA in kidney disease development.  MANBA is a lysosomal 
enzyme that participates in the post-translational modification of proteins by hydrolysis of the 
beta-D-mannose residues. Genetic deletion of Manba in mouse models was associated with 
neurological defects and tissue deposits such as observed in the kidney. 
Recent reports highlight the role of lysosomes and lysosomal dysfunction in CKD 
development [306]. Lysosomes are acidic organelles that play an important role in 
macromolecule degradation and recycling. Fabry’s disease, cystinosis and neuronal ceroid 
lipofuscinosis are primary genetic diseases caused by loss-of-function mutations in lysosomal 
enzymes [306-308]. While many lysosomal enzyme mutations present with primary central 
nervous system defects, these mutations are also associated with altered kidney function and 
ultimately lead to CKD. Renal tubules reabsorb more than 100 liters of fluid and large amounts of 
organic and inorganic matter to maintain homeostasis. Renal tubule cell lysosomes seem to play 
an important role in recycling and uptake of urinary substances [307]. Accumulation of toxic 
substances have been observed in cytinosis and Fabry’s disease that likely result in tubule cell 
death and dysfunction, further fibroblast activation, and structural defect. Further studies will be 
needed to study the role of Manba in renal tubule cells. 
While our present study mostly focused on functional annotation of CKD GWAS hits, the 
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kidney-specific eQTL maps will likely be essential to the understanding of other traits linked to the 
kidney, for example metabolite levels and hypertension. Our work nicely illustrates the critical role 
of the kidney in xenobiotic metabolism as one of the key pathways identified by the eQTL 
analysis. The genetic regulation of drug metabolism-associated genes is likely important to 
understand drug effectiveness, toxicity and metabolism. Future studies shall aim to define these 
connections. 
There are several limitations of our work, importantly the sample size. While 100 samples 
obtained from subjects with a single genetic background can identify genotype-driven gene-
expression changes, they have a limited power to identify smaller gene-expression changes. 
Furthermore, the data was obtained from TCGA database with limited clinical characterization, 
including kidney function and structural information. Another limitation of this study is that we 
used the public dataset form TCGA where the kidney cortex has multiple cell types. We are 
currently implementing a new method, called multi-tissue meta-analysis (METASOFT) that was 
developed in GTEx [98] to identify tissue-specific eGenes. METASOFT borrows the statistical 
power from an additional 44 tissues to identify shared and tissue-specific eGenes. For future 
studies, we will need to perform cell-type-specific analyses with single-cell resolution.  
Despite these potential deficiencies, the dataset will be critically important for 
interpretation of current and future GWAS studies and traits that are likely related to kidney 
function, such as metabolite levels and blood pressure-associated genes, to name a few. While 
proximity-based analysis has been popular in the past, our first pass eQTL analysis does not 
seem to support previously proposed CKD target genes, but highlights the potential role of a set 
of different genes and steers the field to refocus our attention. This analysis identified MANBA as 
a gene that has not previously been implicated in kidney disease development. 
2.5. Materials and Methods 
Subjects 
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99 normal human kidney cortex samples including genotype (Affymetrix Genome-Wide 
Human SNP Array 6.0) and RNA-seq expression profiles were obtained from The Cancer 
Genome Atlas (TCGA) through the TCGA Data portal at https://tcga-data.nci.nih.gov/tcga/. 
Genotype quality control and imputation 
Quality control was performed as follows: Individuals with call rate less than 95%, with 
ambiguous gender, were removed. Samples that have excessive and reduced proportion of 
heterozygosity rate were removed for DNA sample contamination or inbreeding. To further 
examine sample contamination, we examined genome identity-by-descent (IBD), cryptic 
relationships, and sample duplication. IBD was computed pairwise between all samples using 
genome-wide genotype data. To avoid genotyping calling error, we excluded SNPs with missing 
rates > 0.05, minor allele frequency (MAF) < 0.05, Hardy-Weinberg equilibrium (HWE, p-value < 
1.0E-3). We then performed PCA against 1000 Genomes samples that have European ancestry 
and removed samples in our analyses that are deviated from the cluster.  After QC, we had 96 
individual samples that we used for downstream eQTL analyses. 
SNPs that passed quality control were further subject to haplotype phasing using 
SHAPEIT2 [282], and genotype imputation using IMPUTE2 [62], with 1000 Genomes Project 
phase 3 haplotypes as a reference. The imputed genotypes were subjected to second round 
quality control with missing rates <0.05, MAF > 0.05, HWE P-value > 1.0E-6 using Plink.[309]  
Gene expression data processing 
We performed RNA-seq data QC and normalization following the standards in the GTEx 
project.[92] We excluded genes whose mean RNA-Seq by Expectation Maximization (RSEM) 
value was less than 1, and then transformed the RSEM values as follows: (1) quantile 
normalization across samples; (2) rank values across samples followed by mapping to normal 
standard (namely, inverse normal transformation); (3) probabilistic estimation of expression 
residuals (PEER) with available information from samples (gender and age), because these two 
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covariates could have an effect on gene expression; (4) transformation of the residuals of each 
gene to standard normal distribution N (0,1) for each. 
cis-eQTL analysis, identification of eSNPs and eGenes, and network analyses 
We used 1 Mb from transcription start site (TSS) to define cis-eQTL window for each 
gene. The nominal p-values for the SNP-gene pairs in this window were generated using Matrix 
eQTL[283], which performed linear regression on the transformed residuals with the 
corresponding imputed genotypes.  To address multiple comparisons of many SNPs in LD for a 
given gene, we applied the permutation procedure using FastQTL[284], which generated an 
empirical p-value for each gene. We then used the Storey approach to calculate q-values[285], 
and defined genes with a significant q-value (≤ 0.05) as eGenes.  In addition, we generated a list 
of all significantly associated SNP-gene pairs by calculating the threshold of significant nominal p-
value for each eGene based on the permutation method. 
The eGene network analyses were generated using of QIAGEN's Ingenuity Pathway 
Analysis (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity). 
Histone Mark and Transcription Factor Binding Site Enrichment Analysis  
Each histone tail modification marks a different regulatory region of the genome. We use 
this information to discover which regulatory regions the eSNPs were localized to, and to interpret 
what their function could be. The enrichment analysis considered the odds ratio of significant 
SNPs compared to the 1000 null sets of variants. The null sets of variants were matched for 
number, distance to TSS, and allele frequency of eSNPs. To avoid enrichment bias, we pruned 
the eSNPs so that no pair of SNPs had an r2 greater that 0.2 using PLINK (--exclude range --
indep-pairwise 50 5 0.2). 
We acquired the histone marks from human kidney proximal tubule cells that we 
previously published[166], as well as from human kidney tissues at the Roadmap Epigenome 
Project (GSM621634, GSM670025, GSM621648, GSM772811, GSM621651, GSM1112806, 
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GSM621638). Human kidney cell (HKC8) ChIP-seq data can be accessed at Gene Expression 
Omnibus (GSE49637), and Transcription Factor ChIP-seq (161 factors) from ENCODE project 
TFBS clusters (V3) 
(http://hgdownload.cse.ucsc.edu/goldenpath/hg19/encodeDCC/wgEncodeRegTfbsClustered/).  
GWAS SNPs enrichment in kidney cis-eQTLs 
 To determine whether disease traits in our SNPs were enriched, we obtained eGFR-
associated GWAS SNPs from the CKDGen Consortium (http://ckdgen.imbi.uni-freiburg.de) and 
several other studies (Table S6). This yielded 67 leading SNPs. We obtained other GWAS-
identified SNPs from the National Human Genome Research Institute catalog (NHGRI) 
(www.ebi.ac.uk/gwas; accessed date: 9/30/2015). 
 For the NHGRI GWAS SNPs, we randomly sampled a matched number of SNPs (n=67) 
from each trait: digestive system disease, nervous system disease, immune system diseases, 
cardiovascular disease, biological processes, other traits, and body measurement. We took SNPs 
from traits that have comparable number of SNPs to kidney diseases (n=110). We expanded the 
list of GWAS SNPs by including tagging SNPs that are in r2 ≥ 0.8. We later removed SNPs that 
are in the same LD before we performed cis-eQTL analysis using Matrix eQTL. We set the cis-
eQTL discovery p-value threshold to 1.0E-2 to compromise for the number of SNPs overlapped at 
each group and the weak multiple hypothesis effect (Table S1).  The enrichment significance was 
computed using Fisher’s exact test, and we compared each trait against all other traits whether or 
not they are in the cis-eQTL. We ran the test for all groups as mentioned above. 
Integrative statistical analysis of kidney eQTL and kidney function GWAS 
To integrate the kidney eQTL and kidney function GWAS results, we applied the 
Bayesian colocalization approach coloc.[295, 296] In short, coloc used summary statistics to test 
for colocalization of GWAS and eQTL signals with the LD information. Coloc supports multiple 
hypotheses and can distinguish insufficient association from colocalization or distinct 
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associations. Coloc uses posterior probabilities to measure the likelihood of each hypothesis, with 
the prior beliefs of association and colocalization, and the data on genetic association with 
disease and gene expression. 
The five hypotheses used in the analyses were: H0: No association with either trait; H1: 
Association with trait 1, not with trait 2; H2: Association with trait 2, not with trait 1; H3: Association 
with trait 1 and trait 2, two independent SNPs; H4: Association with trait 1 and trait 2, one shared 
SNP. As criteria for significant results, we used both PP5 > 0.8 and PP4/PP3 > 5 (posterior 
probability from H3 and H4) as criteria [297]. 
Gene Expression correlation with eGFR 
Correlations for the expression of target gene with the eGFR in human kidney samples 
were examined using microdissected-tubule microarray data published last year from 95 human 
cortices.[290] Data were uploaded to Array Express and can be accessed under accession code 
E-MTAB-2502. Pearson’s correlation was applied to the normalized gene expression and the 
eGFR level in R (version 3.2.1.). 
Zebrafish functional experiment 
Zebrafish were maintained according to established Institutional Animal Care and Use 
Committee protocols. Briefly, we injected zebrafish embryos with Manba splice-blocking 
morpholino (MO, GeneTools, Philomath OR) at the one-cell stage at various doses. We 
compared the number of abnormal morphant embryos to control embryos, injected with a 
standard control MO designed by GeneTools, using the chi-square test. We documented the 
development of gross edema at 4 days post-fertilization in live embryos. 
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CHAPTER 3: Cytosine methylation changes in enhancer regions 
of core pro-fibrotic genes characterize kidney fibrosis 
development 
3.1 Abstract  
One in eleven people is affected by chronic kidney disease, a condition characterized by 
kidney fibrosis and progressive loss of kidney function. Epidemiological studies indicate that 
adverse intrauterine and postnatal environments have a long-lasting role in chronic kidney 
disease development. Epigenetic information represents a plausible carrier for mediating this 
programming effect. Here we demonstrate that genome-wide cytosine methylation patterns of 
healthy and chronic kidney disease tubule samples obtained from patients show significant 
differences. We identify differentially methylated regions and validate these in a large replication 
dataset. The differentially methylated regions are rarely observed on promoters, but mostly 
overlap with putative enhancer regions, and they are enriched in consensus binding sequences 
for important renal transcription factors. This indicates their importance in gene expression 
regulation. A core set of genes that are known to be related to kidney fibrosis, including genes 
encoding collagens, show cytosine methylation changes correlating with downstream transcript 
levels. Our report raises the possibility that epigenetic dysregulation plays a role in chronic kidney 
disease development via influencing core pro-fibrotic pathways and can aid the development of 
novel biomarkers and future therapeutics. 
 
3.2 Introduction  
CKD clinical retrospective data indicate that altered nutrient availability during 
development can have a long lasting effect on the development of adult diseases, a phenomenon 
called programming. Hypertension and chronic kidney disease (CKD) present one of the highest 
sensitivities to intrauterine programming [310]. Epigenetic changes caused by altered intrauterine 
nutrient availability have been proposed as the mechanistic link for hypertension and CKD 
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development [311]. Epigenetic modifications are inherited during cell division, thus solidifying “the 
memory or programming” effects of the environment [312].  
The epigenome, which includes the covalent modifications of DNA and its associated 
proteins, and defines DNA accessibility to the transcriptional machinery, is the key determinant of 
outcome after transcription factor binding. At the root of epigenetic modification is the direct 
chemical modification of cytosines by methylation [313]. In different cancer types, 
hypermethylation of tumor suppressor gene promoters has been observed [314]. Increased 
promoter methylation can interfere with transcription factor binding, causing loss of tumor 
suppressor expression and thereby contributing to the malignant transformation [315, 316]. 
Agents that reduce cytosine methylation, for example azacytidine, are now in clinical use and 
associated with improvements in clinical outcomes, especially for patients with myelodysplastic 
syndrome [317]. In addition, mutations of different chromatin-modifying enzymes have been 
described in various cancer types, contributing to alterations in the cancer epigenome [318].  
However, little was known about the epigenome of chronic human diseases as opposed 
to cancers. Most previous studies have been performed on cultured cells, animal models, or 
surrogate cell types (mostly circulating mononuclear cells) [319]. As the epigenome is cell-type-
specific, little mechanistic information can be drawn from cultured cells and surrogate cell types 
[320]. To understand whether epigenetic changes occur and potentially contribute to CKD 
development in human samples, we performed genome-wide cytosine methylation profiling of 
tubule epithelial cells obtained from CKD and control kidneys. We found that core fibrosis-related 
genes show cytosine methylation changes in their gene regulatory regions. In vitro studies 
indicate that cytosine methylation differences play a role in regulating transcript expression. 
Examining the CKD epigenome can be an important first step in understanding the role of 
epigenetics outside the cancer field [321]. 
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3.3 Results  
3.3.1 CKD kidneys show distinct cytosine methylation profile 
For our study, human kidney samples were collected from healthy living transplant and 
surgical nephrectomies and categorized based on their clinical and pathological characteristics 
(Table 3-1). In the initial dataset, we combined samples that are hypertensive and diabetic CKD 
as cases, as the clinical, histological and gene expression profiles of these samples were very 
similar. In the replication dataset, only diabetic CKD (DKD) samples were used. In both datasets, 
the criteria for controls were an estimated glomerular filtration rate (eGFR) greater than 60 
cc/minute/1.73m2, absence of significant proteinuria, and less than 10% fibrosis on histology. 
Samples with significant hematuria or other signs of glomerulonephritis (HIV, hepatitis, or lupus) 
were excluded from the analysis. In summary, 26 samples were used for the initial discovery 
phase, the phenotype analysis was significant for racial diversity, and it included subjects with 
and without diabetes both as cases and controls (Table 3-1). 
To avoid cell-type heterogeneity, we microdissected each renal cortical sample and used 
the tubular epithelial cell portion for the initial analysis. Our and other labs have previously 
published that this fraction represents mainly the proximal tubule portion of the human kidney 
[322]. Genome-wide cytosine methylation analysis was performed on each sample using 
methylation-sensitive and -insensitive isoschizomer enzymes (HpaII and MspI) followed by (HpaII) 
fragment enrichment by ligation-mediated PCR (HELP) [248]. Samples were hybridized on 
NimbleGen whole genome-covering microarrays (1.3 million loci). Focusing on loci that showed 
more than 50% difference in their methylation ratio and a P-value <0.01, we identified 4,751 
differentially methylated regions (DMRs) between control and diseased tubule samples (Figure 3-
1A; complete list provided in Appendix 3). The volcano plot analysis (fold change of methylation 
plotted against the negative log2 of P-value) indicated that 70% of the DMRs showed lower 
methylation levels in CKD (Figure 3-1A). We found that cytosine methylation differences suffice 
for proper clustering and supervised classification of control and CKD kidney samples (Figure 3-
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1B). The computational annotation identified a total of 1,535 unique genes in the vicinity of the 
DMRs. 
 
Gene ontology annotation showed that genes around the DMRs are enriched for cell 
adhesion and development-related functions including collagen, fibronectin, TGF-β and Smad 
proteins (Figure 3-1C), and many of these genes are known to play a critical role in CKD 
development. In summary, microdissected kidney tubule cells showed distinct differences in their 
cytosine methylation patterns in CKD. 
 
Table 3-1 | Demographic, clinical and histological characteristics of the samples 
Characteristics Diseased Healthy P-value 
n 12 14 
Age (years) mean ± SD 68.0 ± 10.81 61.14 ± 11.2 0.11 
Ethnicity    
Asian, Pacific Islander 0 1  
White, non-Hispanic 4 2  
Black, non-Hispanic 4 4  
Hispanic 1 3  
Other and unknown 3 4  
Height (cm) mean ± SD 165 ± 8.69 166.5 ± 8.63 0.6 
Weight (kg) mean ± SD 78.0 ± 22.02 88.32 ±15.93 0.2 
BMI (kg/m2) mean ± SD 27.85 ± 6.41 31.25 ± 5.58 0.18 
Diabetes 6 5  
Hypertension 11 12  
Proteinuria (dipstick) 3.0 ± 1.83 0.36 ± 0.81 1.80E-04 
Serum BUN (mg/dL) mean ± SD 35.0 ± 14.7 17.71 ±5.85 4.60E-04 
Serum creatinine (mg/dL) mean ± SD 3.0 ± 1.61 1.08 ± 0.18 2.00E-03 
eGFR (ml/minute/1.73 m2) mean ± SD 29.0 ± 13.68 70.94 ± 8.35 1.06E-09 
Histology    
Glomerulosclerosis (%) 31.0 ± 31.35 3.31 ±5.52 4.00E-03 
Mesangial matrix expansion 1 ± 0.91 0.17 ± 0.39 0.03 
Tubular atrophy (%) 34.0 ± 24.94 9.82 ± 15.76 6.00E-03 
Interstitial fibrosis (%) 34.0 ± 25.15 5.68 ± 5.07 4.00E-04 
Vascular sclerosis    
Intima 2.0 ± 0.78 0.9 ± 1.1 1.50E-03 
Arterioles 2.0 ± 0.78 0.29 ± 0.62 4.00E-04 
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3.3.2 Validation and external replication of the results 
Internal validation of the results was performed using site-specific primer-based 
amplification of bisulfite-converted genomic DNA and Sequenom MassArray Epityper  
quantification of modified cytosines [323]. This method is based on mass spectrometry that allows 
us to determine absolute methylation levels. We correlated these mass array based absolute 
methylation levels with the HpaII/MspI relative ratios (Appendix 4).  
Figure 3-1 | Statistically significant cytosine methylation differences in chronic kidney 
disease. 
(A) Volcano plot analysis of cytosine methylation differences. The x-axis represents the relative 
cytosine methylation difference of control (CTL) versus CKD samples, the y-axis represents the 
negative log2 of the P-value of that locus. The mean P-value and mean difference of 1.3 million 
loci present on the chips are plotted on the graph. The green and red lines represent the 
statistical criteria used for further analysis (P-value and fold change, respectively). (B) 
Hierarchical cluster analysis of the differentially methylated regions. Each column represents 
changes from one individual kidney sample; blue indicates hypermethylation in CKD, while red 
represents hypomethylation in CKD. The chart below shows the clinical parameters of the 
samples: glomerular filtration rate, diabetes status (DM, diabetes mellitus), sex, and age (aged 
>65 years or <65 years (C) Gene Ontology analysis of the 1,535 DMRs mapped to unique 
genes using DAVID gene ontology annotation groups (biological process level 1 annotation). 
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 External validation was performed on 87 microdissected human kidney tubule epithelial 
samples, 21 from patients with DKD and 66 controls including hypertension (n = 22), diabetes 
mellitus (n = 22) or none (n = 22)) (SYH and KS, unpublished observation). Genome-wide 
methylation profiling of the validation set was performed using Illumina Infinium 450K methylation-
sensitive bead arrays. This method uses site-specific probes for bisulfite-converted DNA, which is 
fundamentally different from the restriction enzyme-based method used in the HELP analysis.  
From the 1,535 unique genes found around DMRs in the initial dataset, we examined 
1,092, as these genes were present also on the Illumina Infinium (and Affymetrix for gene 
expression) arrays (Figure 3-2A). Significant methylation differences were detected for 1,061 
genes, corresponding to 98% of the genes in the original dataset) (Figure 3-2A). The complete list 
of DMRs in the original and the replication dataset can be found in Appendix 4. 
Locus-specific validation was performed for six different genes, including COLIVA1. 
COLIV4A1/A2 are critical basement membrane proteins synthesized by epithelial cells. Increased 
expression is known to be responsible for increasing the thickness of the basement membrane 
and it is considered to be an early change in progressive kidney fibrosis [324]. The COLIVA1 and 
COLIVA2 transcripts are transcribed from a single promoter (Figure 3-2B). This locus showed 
significantly lower cytosine methylation of CKD samples (Figure 3-2C). We examined the 
absolute methylation level of COLIV4A1/2 by MassArray Epityper analysis (Figure 3-2D) in 
control and CKD samples and confirmed the methylation differences between healthy and 
diseased tubule epithelial cells. Next we examined COLIVA1/2 methylation in the validation 
dataset (Infinium arrays from 66 control and 21 DKD samples). Using this dataset, we also 
confirmed the predominant (2 to 12%) hypomethylation of this locus (Figure 3-2E). The 
methylation differences correlated with increased COLIVA1 transcript (Figure 3-2F) and protein 
levels (Figure 3-2G). Using the MassArray Epityper, we also validated the methylation status of 
additional loci (Appendix 5). In summary, the methylation differences appear to be highly 
consistent between the original and validation experiments using multiple different methods.  
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3.3.3 Differentially methylated loci are enriched in kidney-specific gene 
regulatory regions 
Cytosine methylation of promoters is critically important, because it can interfere with TF 
Figure 3-2 | External and internal validation of the observed changes. 
(A) Correlation of the DMRs identified in 26 samples using the HELP method and an external 
dataset containing 87 human kidney samples analyzed using Illumina Infinium 450K arrays. We 
found concordant regulation of 1,061 transcripts (98%) from the 1,092 mapped genes using this 
validation dataset. Of transcripts that showed both differential methylation and expression, 404 
(97%) were confirmed. (B) An example of a DMR identified by the HELP assay and confirmed in 
the validation dataset. This DMR is localized in the intronic region of COLIVA1. (C) Methylation 
status and (D) gene expression of COLIVA1 in the original HELP dataset in control and CKD 
samples. (E) MassArray confirmation of methylation status of the COLIVA1 locus (blue is mean 
+- standard deviation of control samples, red is mean +- standard deviation of CKD samples). 
(F) Methylation status of the COLIVA1 locus in the validation dataset (Infinium 450K arrays). 
The data represent the mean differences in absolute methylation levels of individual cytosines at 
the COLIVA1 locus. (G) Immunohistochemistry of COLIVA1 expression in control (CTL), 
diabetic (DM), DKD and CKD kidneys. 
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binding and thereby modulate transcription (You and Jones, 2012). The number of DMRs 
localized to RefSeq annotated promoters and 5' UTRs was significantly lower (about 50%) than  
the expected ratio (Figure 3-3A). On the other hand, more than half of the DMRs were in gene 
body-related regions. Only a few DMRs localized to exons (approximately 200); the majority of 
the differences we observed were in the intronic regions (Figure 3-3A). We also examined the 
RefSeq annotated genomic distribution of the hypo- and hypermethylated regions (Appendix 6). 
The percentage of hypermethylated regions was similar in the different RefSeq-based annotation 
groups. We found that more loci showed increased methylation at the 3' UTR. In summary, the 
genomic regions that showed differences in their cytosine methylation pattern in CKD were not 
promoters, but intronic and transcription termination regions and 3' UTRs. 
To further understand the functional significance of the DMRs, we generated genome-
wide chromatin annotation maps using cultured human proximal tubular epithelial cells (HKC8). 
First, we performed chromatin immunoprecipitation followed by next-generation sequencing 
(ChIP-seq) for a panel of important histone modifications: H3K4me1, H3K4me2, H3K4me3, 
H3K27ac, H3K27me3, and H3K36me3. Next, we generated gene regulatory annotation maps 
from the panel of ChIP-seq data using the hidden Markov model-based ChromHMM chromatin 
segmentation program [325, 326]. Consistent with the RefSeq-based annotation, there were very 
few DMRs localized to ChromHMM-annotated kidney promoter regions (Figure 3-3B). The 
analysis indicated that 30% of the DMRs localized to enhancer regions, which was the most 
significant enrichment. Similar results were obtained when we generated adult kidney cortex 
ChromHMM maps from published ChIP-seq data (Figure 3-3B) [1].  
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Next, we compared CKD-specific DMRs with chromatin annotation maps of other, 
different cell types using the publicly available ENCODE database (Figure 3-3C). We found that 
CKD-specific DMRs localized mostly to repressed chromatin regions, while transcription and 
enhancer regions showed the second- highest enrichment. The results indicated that DMRs in 
CKD were enriched in kidney-specific gene regulatory regions, mainly (intronic) enhancers. 
Gene regulatory regions are usually characterized by DNase I hypersensitivity (DHS) 
[327], because DNA is usually histone-free in gene regulatory regions so transcription factors can 
bind to these regions. Therefore, we overlapped the DMRs with human fetal kidney and human 
proximal tubule epithelial cell DHS-seq data (Gene Expression Omnibus (GEO) accession 
Figure 3-3 | Chronic kidney disease differentially methylated regions are localized to 
kidney-specific enhancer regions. 
(A) RefSeq annotation of the DMRs. Relative enrichment ratio of the DMRs compared with the 
representation of the different elements on the methylation microarray. TSS, transcription start 
site; TTS, transcription termination site. (B) DMRs overlap with regulatory element (chromatin 
state) annotation maps of renal tubule epithelial cells (HKC8) and adult kidney cortex, indicating 
that most differentially methylated cytosines are localized to enhancer (yellow and orange) 
regions in kidney epithelial cells. The color code annotation of the chromatin state map is 
provided bottom right. (C) Chromatin annotation of the DMRs in five different ENCODE cell lines 
(H1, human embryonic stem cells; HepG2, hepatocytes; HUVEC, endothelial cells; K562, 
erythroid cells; NHLF, human lung fibroblasts). 
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GSM530655). The statistical analysis confirmed that DMRs are enriched in DHS sites in both the 
fetal kidney epithelial dataset and the cultured tubule epithelial cell dataset. In addition, we 
examined whether DMRs that overlap with DHS sites show similarities, by identifying the top 10 
consensus sequences using the MEME software package [328]. To search for TF binding motifs 
among the top 10 sequences, we mapped the sequences to the JASPAR, UniProbe and Transfac 
databases [329]. This analysis highlighted that the DMRs contain consensus-binding sequences 
for transcription factors that play important roles in proximal tubule development, including SIX2, 
HNF, and TCFAP. The list of computationally identified transcription factor consensus motifs is 
shown in Figure 3-4A.  
Figure 3-4 | Chronic kidney disease differentially methylated regions are enriched for 
kidney-specific transcription factor binding sites. 
(A) The DMR and DHS sites contain consensus sequences. The transcription factor binding site 
motifs and their statistical enrichment from the de novo searched consensus sequences in DMR 
and DHS sites. (B) A specific example of an intronic DMR (within the EZR gene). The genomic 
location of the DMR is at the top, followed by the RefSeq representation of EZR; fetal kidney 
(FK)-specific DHS tracks (in blue); HKC8 cell-specific H3K4me1 and H3K4me3 tracks; HKC8 
cell specific ChromHMM annotation of the locus (yellow, enhancer; red, promoter; green, 
transcription-associated region; the full color coding key is shown bottom right) - the sequences 
contain consensus-binding sites for the key kidney transcription factor SIX2/3, with the SIX2/3 
binding motif illustrated as a sequence logo plot below; and adult kidney (AK)-specific H3K4me1 
(blue) and H3K4me3 (green) tracks [1]. 
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Figure 3-4B illustrates our motif analysis. Here a DMR is located in the intronic region of 
the EZR (ezrin) gene. The DMR overlapped with adult kidney and renal tubular epithelial cell-
specific H3K4me1 histone modification, but not with H3K4me3 enrichment. H3K4me1 is a 
specific histone tail modification for enhancer regions, while H3K4me3 is a marker of promoters. 
The ChromHMM-based gene regulatory region annotation confirmed that this region is an 
enhancer in renal epithelial cells (yellow region in the genome).  
These results indicate that by multiple different approaches this DMR is located in a gene 
regulatory region, an enhancer (Figure 3-4B). In addition, this region contained a consensus-
binding sequence for SIX2, further confirming that this is a gene regulatory region. In summary, 
our results indicate that CKD-specific DMRs are located in non-promoter gene regulatory regions, 
mainly enhancers, and contain consensus-binding motifs for renal-specific transcription factors. 
3.3.4  Differentially methylated regions are functionally relevant and 
correlate with transcript levels 
To study the functional significance of DMRs, we first, we examined whether they 
correlate with downstream transcript levels. Gene expression changes were analyzed using RNA 
samples extracted from the same microdissected tubule samples used in the methylation assay. 
Individual RNA samples were hybridized to Affymetrix U133 arrays and the data ware normalized 
and analyzed using established pipelines [322]. From the 1,092 transcripts in close proximity to 
the DMR regions (Figure 3-5A), we identified 415 (approximately 40%) genes showing 
significantly differential expression in the CKD samples (Figure 3-5A).  
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As most DMRs were in non-promoter regions, most transcript changes correlated with 
intronic DMRs (Supplementary file 8). Gene ontology and network analyses highlighted 
differences in cell adhesion (collagens and laminins) and development-related pathways (Figure 
3-5B, C). Specifically, we observed significant enrichment for differential expression and 
methylation in the TGF-β pathway, especially in TGFBR3, SMAD3, SMAD6 and other targets 
Figure 3-5 | Differentially methylated regions correlate with transcript changes. 
(A) The 4,751 DMRs mapped to 1,092 unique genes that were present in the Affymetrix 
arrays. There were 415 transcripts that showed differences both in their methylation status 
and their expression in CKD samples. The RefSeq-based locations of the DMRs are also 
shown. While most differentially methylated regions localize to gene body regions, they also 
show correlation with the expression of many of those genes. Not only are the 415 transcripts 
differentially expressed, they also show differences in their cytosine methylation profiles as 
well. (B) DAVID-based gene ontology annotation of the 415 transcripts. (C) Network chart of 
the genes that are both differentially expressed and methylated (pathways related to 
development are highlighted in orange). (D) Methylation and gene expression level of key 
molecules (RUNX3, RARB, SMAD6) identified by the network analysis in control (CTL) and 
CKD samples. 
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(Figure 3-5D). These genes are known to be critical in CKD development [330, 331]. In summary, 
cytosine methylation changes showed correlation with gene expression differences and identified 
concordant changes in the TGF-β pathway, a well-known regulator of kidney fibrosis 
development. 
3.3.5 Methylation in differentially methylated regions affect gene 
expression in vitro 
To further examine the relationship between cytosine methylation and transcript level 
changes, we analyzed gene expression and cytosine methylation patterns of tubule epithelial 
cells at both baseline and 9 days after treatment with a DNA methyltransferase inhibitor, 
decitabine (5-aza-2-dexoycytidine). We used AffymetrixST1.0 arrays to compare gene expression 
changes and the Infinium 450K arrays to examine cytosine methylation changes in control (n = 3) 
and decitabine-treated cells (n = 4).  
We tested whether there is correlation between in vivo (CKD) and in vitro (decitabine 
treatment) of the DMR and gene expression changes. Decitabine is a cytosine analogue; 
therefore, we hypothesize that after decitabine treatment, the cytosine methylation changes are 
Figure 3-6 | Regulation of transcripts by a DNA methyltransferase inhibitor in in vitro 
cultured human tubular epithelial cells. 
Gene ontology terms of transcripts showing differential expression in the decitabine-treated 
cells. (A) Illustration of regions that showed differential methylation of cultured HKC8 cells 
treated with 0.5 µM decitabine (5'DAC). CTL, control. (B) The interconnected network analysis 
highlighted the differential expression of cell adhesion and developmental pathways. These 
genes are also differentially expressed and methylated in the original CKD dataset. GO, gene 
ontology. 
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the primary cause of transcript level changes. A limitation of the experiment is that decitabine 
induces demethylation of genomic loci that could be different from the CKD DMRs. Large 
numbers of loci showed concordant differential methylation and gene expression changes in CKD 
in vivo as well as after (0.5 µM) decitabine treatment in vitro, indicating that cytosine methylation 
changes in CKD might be the functional drivers of transcript level changes (Supplementary file 9). 
Genes related to cell adhesion (for example, collagen molecules) showed differential methylation 
following decitabine treatment as well (Figure 3-6A, B). In addition, just as we observed before, 
we found that genes related to development and cell adhesion were also differentially expressed 
following decitabine treatment (Figure 3-6B, C).  
SMAD3 appears to be one of the most important mediators of the pro-fibrotic effect in the 
TGF-β and angiotensin II pathways [331]. The SMAD3 locus contained DMRs in both the initial 
and validation datasets. SMAD3 expression levels were lower in both the original and 
confirmation datasets. Decitabine changed the methylation of this locus and subsequently also 
changed SMAD3 transcript levels.  
 To illustrate our findings, while RUNX1 clearly plays an important role in leukemia 
development, it is expressed in both mice and humans in the developing and adult kidneys [332]. 
RUNX1 was also shown to be differentially expressed in CKD tubules [322]. Both the original and 
replication dataset showed differential methylation of this locus (Figure 3-7A, C) and RUNX1 
transcript levels were increased in both datasets (Figure 3-7B, D). RUNX1 DMRs clustered in 
ChromHMM annotated enhancer regions (Figure 3-7G) (with H3K4me1 and DHSs) In vitro 
treatment with decitabine changed the cytosine methylation of this locus, and the changes 
overlapped with the enhancer DMRs (Figure 3-7E).  
Subsequent to the DMR change of this locus, we also observed an increase in RUNX1 
transcript levels both in vivo and in vitro (Figure 3-7F). As decitabine did not change the 
methylation of the RUNX1 promoter and affected only the methylation levels of the enhancer site, 
the result potentially indicates a causal relationship between enhancer-related DMRs and gene 
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expression changes. The concordant changes in cytosine methylation and gene expression in 
CKD and in vitro (following DNA methyltransferase inhibitors) indicate that DMRs are potential 
drivers of critical CKD gene expression. 
 
3.4 Discussion and Conclusion 
 While epigenetic dysregulation has been suggested as a mechanism for the 
Figure 3-7 | Gene body cytosine methylation changes drive gene expression differences. 
RUNX1 methylation and gene expression were examined. only(A,B) In the original discovery 
dataset, the gene body region of RUNX1 was hypomethylated (A) and the corresponding 
transcript level was increased (B) in the CKD (discovery) dataset. CTL, control. (C,D) The 
differential methylation (C) and expression (D) of RUNX1 in the DKD replication dataset. (E,F) 
Transcript levels are increased (F) in vitro in cultured tubules after decreasing the methylation 
level of the locus following 0.5 µM decitabine (DAC) treatment (E). (G) Genomic representation 
of the RUNX1 locus showing DMRs in the DKD dataset and in the CKD dataset. Different tracks 
are shown for the RUNX1 locus, including RefSeq gene, DMRs in the DKD dataset, DMRs in 
the CKD cells, and histone ChIP-seq data for H3K4me1 and H3K4me3 for adult kidney cortex 
and DHS sites from fetal kidneys. In addition, ENCODE-based transcription factor binding sites 
are also shown. 
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development of many diseases, little is known about the epigenome of normal and diseased 
human cells and organs. Here we describe cytosine methylation differences in tubule cells 
obtained from patients with CKD. We found that CKD DMRs have many special features. First, 
most loci showed consistent cytosine methylation differences in CKD. These changes were 
smaller than what has been described in the cancer literature previously. While the absolute 
differences were modest, the identified loci showed highly consistent changes even across 
different datasets and platforms. Unexpectedly, we found that most methylation differences were 
localized outside of promoter areas, with promoter regions markedly spared from cytosine 
methylation differences.  
Our results indicate that the differentially methylated regions were located mainly at 
candidate enhancers. We found that the DMRs contain consensus-binding motifs for key renal 
transcription factors (HNF, TCFAP, SIX2). Furthermore, cytosine methylation levels correlated 
with baseline gene expression changes. These epigenetically distinct but morphologically similar 
cells also showed differences in their cytokine response. We illustrated our findings in a model 
hypothesizing that enhancer DMRs might modify TF binding and thereby modify downstream 
transcript levels. Based on our results, we propose that cytosine methylation changes are 
causally linked to transcript levels and phenotype development.  
As hypertensive and diabetic tubule samples showed similarities both in cytosine 
methylation and gene expression changes, the observed changes are likely to be part of a 
common mechanism of progression. This may be expected, as phenotypically the 
tubulointerstitial fibrosis of DKD and hypertensive CKD is similar. In addition, we found that DMRs 
were enriched for genes related to kidney development, many of them no longer expressed in the 
adult kidney. The DMR regions also contained binding sites for key kidney developmental factors 
such as SIX2, HNF, and TCFAP.  
One possible interpretation of our findings is that the epigenetic differences are 
established during development. This is the time when the cell-type-specific epigenome is 
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established and these genes and transcription factors play functional roles. Therefore, they can 
possibly provide the mechanistic link between fetal programming and CKD development - the 
Brenner-Barker hypothesis put forward many decades ago [333, 334], proposed that nutrient 
availability during development has a longlasting programming role in hypertension and CKD 
development.  
In addition, reactivation of the developmental pathways is also needed during organ 
injury repair [335]. We can also speculate that the altered developmental wiring of these 
pathways continues to play a role later on as alterations observed after repair. Indeed, control 
and CKD kidney epithelial cells showed not only cytosine methylation differences but also 
different responses to cytokine treatment.  
A limitation of our results remains that our samples were collected in a single center. 
Furthermore, base pair resolution results will likely help to refine the more precise location of 
DMRs and the methylation differences in the future. While microdissection is an excellent 
separation method to generate a homogenous tubular epithelial cell population from the kidney, 
the potential risk for increased cell type heterogeneity in CKD remains. As isolated and cultured 
cells continued to show many of the epigenetic and transcriptional differences, it is more likely 
that the observed differences are not related to cell type heterogeneity. In summary, while it has 
long been speculated that epigenetic dysregulation might occur in non-cancerous diseases, 
including CKD, here we provide experimental evidence for cytosine methylation changes in 
human kidney tissue samples, opening the possibility that they play a role in CKD development. 
  
3.5 Materials and Methods  
Ethics statement 
The clinical study used the cross-sectional design. Kidney samples were obtained from 
routine surgical nephrectomies. Samples were de-identified and the corresponding clinical 
information was collected by an individual who was not involved in the research protocol. The 
study was approved by the Institutional Review Boards of the Albert Einstein College of Medicine 
  
 
79 
Montefiore Medical Center (IRB#2002-202) and the University of Pennsylvania. Histological 
analysis was performed by an expert pathologist (IRB#815796). 
Tissue handling and microdissection 
Tissue was placed into RNALater and manually microdissected at 4C for glomerular and 
tubular compartments as described earlier. Dissected tissue was homogenized and RNA was 
prepared using RNAeasy mini columns (Qiagen, Valencia, CA, USA) according to the 
manufacturer's instructions. RNA quality and quantity was determined using Lab-on-Chip Total 
RNA PicoKit (Agilent BioAnalyzer, Santa Clara, CA, USA). Only samples without evidence of 
degradation were used. Genomic DNA was extracted by phenol chloroform protocol for HELP 
analysis and the DNAeasy kit was used for the Infinium platform. 
DNA methylation analysis by HELP 
The HELP assay was carried out as previously published [336]. Intact DNA of high 
molecular weight was corroborated by electrophoresis on 1% agarose gels in all cases. One 
microgram of genomic DNA was digested overnight with either HpaII or MspI (NEB, Ipswich, MA, 
USA). The digested DNA was used to set up an overnight ligation of the HpaII adapter using T4 
DNA ligase. The adapter-ligated DNA was used to carry out the PCR amplification of the HpaII- 
and MspI-digested DNA as previously described [248]. Both amplified fractions were submitted to 
Roche NimbleGen Inc. (Madison, WI, USA) for labeling and hybridization onto a human hg18 
high-density custom-designed oligonucleotide array (50-mers) containing 2.6 million loci. HpaII-
amplifiable fragments are defined as genomic sequences contained between two flanking HpaII 
sites found within 200 to 2,000 bp of each other. All microarray hybridizations were subjected to 
extensive quality control using the following strategies. First, uniformity of hybridization was 
evaluated using a modified version of a previously published algorithm [337] adapted for the 
NimbleGen platform, and any hybridization with strong regional artifacts was discarded and 
repeated. The raw data can be accessed under GSE49557. 
HELP data processing and analysis 
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Signal intensities at each HpaII amplifiable fragment were calculated as a robust (25% 
trimmed) mean of their component probe-level signal intensities. Any fragments found within the 
level of background MspI signal intensity, measured as 2.5 mean absolute differences (MAD) 
above the median of random probe signals, were categorized as “failed”. The failed loci therefore 
represent the population of fragments that did not amplify by PCR, whatever the biological or 
experimental cause (for example, genomic deletions and other sequence errors). On the other 
hand, “methylated” loci were so designated when the level of HpaII signal intensity was similarly 
indistinguishable from background. PCR-amplifying fragments (those not flagged as either 
“methylated” or “failed”) were normalized using an intra-array quantile approach wherein 
HpaII/MspI ratios are aligned across density-dependent sliding windows of fragment size-sorted 
data. The log2 (HpaII/MspI) was used as a representative for methylation and analyzed as a 
continuous variable. For most loci, each fragment was categorized as either methylated, if the 
centered log HpaII/MspI ratio was less than zero, or hypomethylated if the log ratio was greater 
than zero. 
Statistical analysis of HELP data was performed using the statistical software R version 
2.13.1 [337]. A two-sample t-test was used for each gene or locus to summarize methylation 
differences between the two clinical groups (cases and controls). Genes were ranked based on 
the magnitude of this test statistic and a set of differentially methylated loci with P-value <0.01 
and a fold change >0.5 was identified. 
Quantitative DNA methylation analysis by MassArray epityping 
Validation of HELP microarray findings was carried out by matrix-assisted laser 
desorption/ionisation-time of flight (MALDI-TOF) mass spectrometry using EpiTyper by 
MassArray (Sequenom, San Diego, CA, USA) on bisulfite-converted DNA as previously 
described (Zhou, Opalinska et al. 2011). MassArray primers were designed to cover the flanking 
HpaII sites for a given HpaII-amplifiable fragments (HAF), as well as any other HpaII sites found 
up to 2,000 bp upstream of the downstream site and up to 2,000 bp downstream of the upstream 
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site, in order to cover all possible alternative sites of digestion. HAF is defined by those fragments 
where two HpaII sites are located 200-2000 bp apart with at least some unique sequence 
between them and selected those located at gene promoters and imprinted regions. 
Gene expression analysis using Affymetrix arrays 
Transcript levels were analyzed using Affymetrix U133A and 1.0ST arrays. Probes were 
prepared using an Affymetrix 3′ IVT kit. After hybridization and scanning, raw data files were 
imported into Genespring GX software (Agilent Technologies). Raw expression levels were 
normalized using the RMA16 summarization algorithm. Genespring GX software was then used 
for statistical analysis; the data were above the 20th percentile when filtered by expression. We 
used a Benjamini-Hochberg multiple testing correction with a P-value <0.05. Heatmaps of 
methylation data and gene expression data were generated using an unsupervised hierarchical 
clustering method calculated by squared Euclidean distances. Methylation data used in clustering 
have a P-value <0.00015 and a fold change ≥0.5. The raw data can be accessed through 
accession GSE48944. 
Gene ontology and transcription factor binding sites 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
bioinformatics package was used for gene ontology and pathway analysis. In addition, Ingenuity 
Pathway Analysis (IPA, Redwood City, CA, USA) was used to generate networks. 
Sequences of DMRs (n = 4,751) were lifted over from hg18 to hg19 using UCSC 
Genome Browser Utilities. The regions were then intersected with fetal kidney or human kidney 
epithelial-specific DHS peaks (data from GEO GSM530655); a total of 364 overlapping regions 
were used. Motif weight matrices overrepresented in the overlapped sequences were identified 
using MEME version 4.8.0 [328] on the 364 regions with parameter -oc -nmotifs 10 -minw 8 -
maxw 50. 
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Adult kidney ChIP-seq data were acquired from the Roadmap database (GEO 
accessions number GSM670025, GSM621638). The overlap was set to be a minimum of 1 bp in 
length. 
Motif searching 
We compared de novo motifs to motifs available as part of various databases, including 
Transfac, version 2011.1, Jaspar Core, and UniPROBE using TOMTOM software [329], version 
4.8.1. TOMTOM parameters were set to their default values during motif comparisons. When 
partitioning the de novo motifs, assigning each to a single category, the order of match 
assignment preference was to Transfac, Jaspar Core, UniPROBE, and then to the novel motif 
category. 
Cell lines 
HKC8 cells were kindly provided by Lorainne Racusen (Johns Hopkins University) and 
were cultured in DMEM/F12 medium supplemented with 2.5% fetal bovine serum, antibiotics and 
insulin, transferrin and selenium. Cells were incubated with 0.5 µM decitabine on days 2, 4, 6, 
and 8 and harvested on day 9. RNA was isolated using a Qiagen RNeasy kit labeled using an 
Ovation transcript labeling kit and hybridized onto Affymetrix Human ST1.0 arrays.  
Chromatin immunoprecipitation sequencing 
HKC8 cells were harvested and crosslinked with 1% formaldehyde when they reached 
80% confluency on culture plates. Chromatin was sheared using a Bioruptor and 
immunoprecipitated using H3K4me1 (Abcam ab8895, Cambridge, MA, USA), H3K4me2 (Abcam 
ab11946), H3K4me3 (Abcam ab8580), H3K36me3 (Abcam ab9050), H3K27ac (Abcam ab4729) 
and H3K27me3 (Millipore 07-499, Billerica, MA, USA) marks. ChIP was performed as described 
in the manual of MAGnify™ Chromatin Immunoprecipitation System (Invitrogen, Grand Island, 
NY, USA). Quantitative real-time PCR was performed to ensure the quality of the ChIP product. 
The ChIP product was assessed for size, purity, and quantity using an Agilent 2100 Bioanalyzer 
(Agilent Technologies). Library preparation and sequencing were performed at the Einstein 
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Epigenome Center. Sequence reads (100 bp) were generated from llumina HiSeq 2000 [338]. 
Reads were aligned to the reference genomes (NCBI build 37, hg19) using Bowtie (v 0.12.7) 
[339]. Repetitively mapped and duplicate reads were excluded. The data can be accessed using 
accession GSE49637. 
ChIP-seq data analysis 
We used the MACS version 1.4.1 (model-based analysis of ChIP-Seq) peak-finding 
algorithm to identify regions of ChIP-Seq enrichment over background [340]. A false discovery 
rate threshold of enrichment of 0.01 was used for all datasets. The resulting genomic coordinates 
in BED format were further used in ChromHMM v1.06 for chromatin annotation. The following 
parameters were used: -Xmx1600M -jar ChromHMM.jar BinarizeBed hg19 -Xmx2000M -jar 
ChromHMM.jar LearnModel 10 hg19. 
DNase I hypersensitive site analysis 
Human kidney DHS sequencing data (GEO GSM530655) was analyzed with MACS 
(v.1.4.1). The resulting peaks were overlapped with the differentially methylated regions. The 
control random genomic loci were generated using Regulatory Sequence Analysis Tools [341]. 
Based on the data property of differentially methylated regions, we used the same number of 
fragments (4,751) and the same average fragment size (443 bp) as parameters for the random 
loci. 
Illumina infinium 450K BeadChip arrays 
Genomic DNA (200 ng) was purified using the DNeasy Blood and Tissue Kit (Qiagen, 
Hilden, Germany) following the manufacturer’s protocol. Purified DNA quality and concentration 
were assessed with a NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA) and by 
Quant-iT™ PicoGreen® dsDNA Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) prior to 
bisulfite conversion. Purified genomic DNA was bisulfite converted using the EZ DNA Methylation 
Kit (Zymo Research, Orange, CA, USA) following the manufacturer’s protocol. Bisulfite DNA 
quality and concentration were assessed, following the Illumina 450K array protocol, the bisulfite 
  
 
84 
converted sample was whole-genome amplified, enzymatically digested, and hybridized to the 
array, and then single nucleotide extension was performed. 
Chips were scanned using an Illumina HiScan on a two-color channel to detect Cy3-
labeled probes on the green channel and Cy5-labeled probes on the red channel. Illumina 
GenomeStudio Software 2011.1 Methylation Module 1.8 was used to read the array output and 
conduct background normalization. The level of DNAm for 428,216 probes in our sample dataset 
was intersected with the expanded annotation for further analyses. All samples were run together 
to eliminate the batch effect according to the pipelines established by Illumina Genome Studio. 
The full dataset can be accessed in GEO under GSE50874.  
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CHAPTER 4: Conclusion 
4.1. Summary of results and discussion 
The work described in the dissertation aimed to understand genetic and epigenetic 
factors related to CKD and CKD development. Our eQTL analysis opens the door to considerable 
future research in gene regulation in the human kidney. While a human-body eQTL map has 
been generated through GTEx, a kidney-specific eQTL map was not available through the public 
database due to organ allocation and transplantation. In addition, published results showed that 
eQTL performed from imputed gene expression for unavailable tissue types such as the human 
kidney does not have enough power to detect tissue-specific eQTLs [305]. For these reasons, our 
kidney eQTL analysis using RNA sequencing-based gene expression in human kidney samples 
is an important resource for the research community.  
The eQTL results showed that kidney eSNPs are localized to kidney-specific regulatory 
regions: promoters, enhancers and TF binding sites, which suggested regulatory functions for 
these eSNPs. We used the kidney eSNPs to interpret CKD-associated SNPs using both direct 
overlap and Bayesian colocalization methods. We identified a short list of genes that are likely 
responsible for the association observed between genotype and kidney disease traits in large-
scale GWAS. Among the 9 identified genes, a few target genes have presented with kidney 
phenotypes in knockout transgenic mice, including Cystatin 9 (CST9) and PGAP3.  
These examples validated that the colocalization method can identify kidney-relevant 
target genes. We validated one of the target gene, MANBA. as a likely causal gene for genetic 
variants on chromosome 4 that are associated with CKD. We found that the risk allele is 
associated with lower MANBA gene expression level in human kidney samples.  
From zebrafish experiments, we observed that lower MANBA expression is causally 
related to kidney disease development. Morpholino knockdown of Manba resulted in pericardial 
edema, indicating a functional role of MANBA in kidney disease development. MANBA is a 
lysosomal enzyme that participates in the post-translational modification of proteins by hydrolysis 
  
 
86 
of the beta-D-mannose residues. Manba knockout mice were associated with neurological 
defects and presented with cellular deposits in the kidney. 
Lysosomal dysfunction in CKD development has been observed through several loss-of-
function mutations in lysosomal enzymes that causes genetic diseases with altered kidney 
function and ultimately lead to CKD. For example, accumulation of toxic substances has been 
observed in Fabry’s disease and cystinosis that likely result in tubule cell death and dysfunction, 
further fibroblast activation, and structural defect. Further studies will be needed to study the role 
of Manba in kidney tubule cells.  
As GWAS explain little of the heritability of CKD, another possible mediator could be 
epigenetics. Little was known about the epigenome of normal and diseased human kidneys when 
we performed our cytosine methylation experiments and analysis in 2012. We were the first 
researchers to describe genome-wide cytosine methylation differences in tubule cells obtained 
from patients with CKD.  
We found that while DMRs associated with CDK do not have the scale of difference 
observed in cancer studies, the differences are very stable and consistent in patient samples 
across different sample cohorts and different assay platforms. To our surprise, we found that 
CKD DMRs are depleted from promoter regions and enriched in enhancer regions. These 
enhancer regions are enriched with consensus-binding motifs for key renal transcription factors 
(HNF, TCFAP, SIX2). We observed consistent methylation and gene expression correlation in 
different cohorts as well. 
We illustrated our findings in a model hypothesizing that enhancer DMRs modify TF 
binding and thereby modify downstream transcript levels. Based on our results, we propose that 
cytosine methylation changes are causally linked to transcript levels and phenotype development.  
 
4.2. Future direction 
Our present study mostly focused on functional annotation of CKD GWAS variants, but 
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kidney-specific eQTL maps would be useful to the understanding of other phenotypes that are 
associated with kidney, including metabolite levels and hypertension. Our work illustrates the 
critical role of the kidney in xenobiotic metabolism as one of the key pathways identified by the 
eQTL analysis. The genetic regulation of drug metabolism-associated genes is likely important to 
understand drug effectiveness, toxicity and metabolism. Further experiments are needed to 
validate these connections. 
One remaining question for eQTL study is how to identify the causal variant among a 
cluster of variants that all present similar significance association with the target gene. To perform 
the experimental validation and to understand how many variants at each locus function together, 
a high-throughput method including massively parallel reporter assay (MPRA) [342], or a modified 
version that shows improved throughput and sensitivity [343], can perform systematic 
examination. For in vivo analysis, expression of the identified regulatory regions in zebrafish can 
elucidate the cell-type specificity of the regions. This can be performed by attaching the 
regulatory regions to the green fluorescence protein construct, and then using the transposon 
system to integrate the sequence to the zebrafish genome. 
There remain some limitations on our work, importantly sample size. While 100 samples 
obtained from subjects with a single genetic background can identify genotype-driven gene-
expression changes, they have a limited power to identify smaller gene-expression changes. 
Furthermore, the genotyping and RNA-seq data were obtained from the TCGA database with 
limited clinical characterization of kidney function and structural information. Greater sample size 
as well as clear clinical parameters will increase the power to detect kidney-specific gene 
expression changes associated with variants. 
For the cytosine methylation study, we also had the limitation that our sample size was 
small and the samples were collected in a single center. In addition, our analysis was performed 
using array-based method, but in order to refine the DMR location, we can apply bisulfite 
sequencing to the samples, which will increase the resolution (location and methylation level). 
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With current genotyping results available for some of the human kidney samples, it is also 
possible to perform methylation QTL. With the advance of experimental tools, site-specific 
manipulation will allow us to modify DNA methylation and differentiate the functional 
consequences using CRISPR/Cas9 system [344].  
For both studies, we encountered issues arising from the cell type heterogeneity. 
Although the majority of the cell types in the cortex are proximal, distal and convoluted tubules, 
there are other cell types in the cortex, including mesangial cells, podocytes, and endothelial 
cells. Ideally, we would have to perform microdissection and separated the tubule and glomeruli 
compartments, but it was not feasible using the publicly available dataset that we used to perform 
eQTL analysis. Future studies using single-cell resolution transcriptome analysis in the kidney will 
be essential to define the trancriptome signature of different cell types and the expression of cell-
type-specific genes. 
In summary, an integrative analysis performed using clinical parameters, genotype, gene 
expression and methylation datasets may advance the identification of causal genomic loci that 
regulate gene expression and cell phenotypes involved in the development of CKD. 
  
  
 
89 
APPENDIX 
 
Appendix 1 | List of CKD associated SNPs. List of SNPs curated manually from all kidney-
function-associated GWAS. 
Gene 
Symbols 
SNP Chr Pos (b37) Freq Effect Size 95%CI/S
E 
p-
value 
Referenc
e 
Associatio
n  
parameter  
SYPL2 rs1213606
3 
1 110014170 0.3 -0.0045 0.0008 4.71E-
08 
Pattaro 
2015 
eGFRcrea 
SDCCAG8 rs2802729 1 243501763 0.43 -0.0046 0.0008 2.20E-
08 
Pattaro 
2015 
eGFRcrea 
SARS, CELSR2,  
PSRC1,  
MYBPHL, 
SORT1,  PSMA5,  
SYPL2, 
ATXN7L2,  
CYB561D1,  
AMIGO1, 
GPR61,  GNAI3,  
AMPD2, GSTM2,  
GSTM4,  
GSTM1, GNAT2 
rs1933182 1 109999588 0.3 -0.008 0.001 1.30E-
08 
Köttgen 
2010 
eGFRcrea 
VAV3 rs1701960
2 
1 108188858 0.19 1.17 1.11-1.24 6.80E-
09 
Kiryluk 
2014 
IgA-NP 
CFHR1,3 rs6677604 1 196686918 0.073 0.68  2.96E-
10 
Gharavi 
2011 
IgA-NP 
CACNA1S rs3850625 1 201016296 0.12 0.0083 0.0013 6.82E-
11 
Pattaro 
2015 
eGFRcrea 
MTX1-GBA rs2049805 1 153461604 0.17 0.0072 0.001 1.80E-
12 
Okada 
2012 
BUN 
ANXA9/LASS2 rs267734 1 150951477 0.2 0.01 0.002 1.20E-
12 
Köttgen 
2010 
eGFRcrea 
DNAJC16 rs1212407
8 
1 15869899 0.3 -0.0097 0.0011 1.50E-
17 
Pattaro 
2012 
eGFRcrea 
SOX11 rs1686417
0 
2 5907880 0.05 -0.011 0.003 4.50E-
08 
Köttgen 
2010 
CKD 
DDX1 rs6431731 2 15863002 0.06 0.0127 0.0023 4.30E-
08 
Pattaro 
2012 
eGFRcrea 
CDCA7 rs4972593 2 174462854 0.14 1.81 1.47-2.24 3.85E-
08 
Sandholm 
2013 
T1DK-
FemaleOnly 
LRP2 rs4667594 2 170008506 0.47 0.0044 0.0008 3.52E-
08 
Pattaro 
2015 
eGFRcrea 
AFF3, TSC22D4, 
NYAP1 
rs7583877 2 100460654 0.289 1.29 1.18-1.40 1.20E-
08 
Sandholm 
2012 
T1-ESRD 
CPS1 rs7422339 2 211540507 0.32 1.11 1.07-1.15 7.54E-
09 
Pattaro 
2015 
CKD 
RND3 rs7560163 2 151637936 0.14 0.75 0.68–0.87 7.00E-
09 
Palmer 
2012 
T2-ESRD 
PAX8 rs1112317
0 
2 113695411 0.35 0.0051 0.0008 3.30E-
10 
Okada 
2012 
BUN 
IGFBP5 rs2712184 2 217682779 0.42 0.0053 0.0008 1.33E-
10 
Pattaro 
2015 
eGFRcrea 
ALMS1/NAT8 rs13538 2 73868328 0.23 0.009 0.002 4.50E-
14 
Köttgen 
2010 
eGFRcrea 
GCKR rs1260326 2 27730940 0.41 0.009 0.001 3.00E-
14 
Köttgen 
2010 
eGFRcrea 
PLA2R1 rs4664308 2 160917497 0.43 0.43859649
1 
0.38-0.51 8.60E-
29 
Stanescu 
2011 
IMN 
WNT7A rs6795744 3 13906850 0.15 0.006 0.0011 3.33E-
08 
Pattaro 
2015 
eGFRcrea 
SKIL rs9682041 3 170091902 0.13 0.0068 0.0012 2.58E-
08 
Pattaro 
2015 
eGFRcrea 
ETV5 rs1051380
1 
3 185822353 0.13 -0.0072 0.0012 1.03E-
09 
Pattaro 
2015 
eGFRcrea 
ST6GAL1 rs7634389 3 186738421 0.44 1.13 1.09-1.18 7.27E-
10 
Li 2015 IgA-NP 
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TFDP2 rs347685 3 141807137 0.28 0.009 0.001 3.00E-
11 
Köttgen 
2010 
eGFRcrea 
MECOM rs1685372
2 
3 170633326 0.29 0.0064 0.0008 2.70E-
14 
Okada 
2012 
BUN 
LRIG1-KBTBD8 rs1306900
0 
3 66881640 0.17 0.0093 0.001 1.40E-
19 
Okada 
2012 
BUN 
BCL6-LPP rs1093732
9 
3 189196412 0.69 0.01 0.0009 8.80E-
30 
Okada 
2012 
BUN 
FAM47E, 
STBD1,  
CCDC158,  
SHROOM3 
rs1314635
5 
4 77412140 0.21 -0.0117 0.0013 6.60E-
11 
Okada201
2 
eGFRcrea 
NFKB1 rs228611 4 103561709 0.47 -0.0056 0.0008 3.58E-
12 
Pattaro 
2015 
eGFRcrea 
SHROOM3 rs1731972
1 
4 77368847 0.44 -0.012 0.002 1.20E-
12 
Köttgen 
2009 
eGFRcrea 
RGS14 rs1265481
2 
5 176726797 0.36 -0.0056 0.001 2.90E-
08 
Okada 
2012 
eGFRcrea 
DAB2 rs1195992
8 
5 39397132 0.44 -0.009 0.001 1.40E-
17 
Köttgen 
2010 
eGFRcrea 
ZNF204 rs7759001 6 27341409 0.24 0.0051 0.0009 1.75E-
08 
Pattaro 
2015 
eGFRcrea 
HLA-DPB2 rs1883414 6 33086448 0.24 0.78  4.84E-
09 
Gharavi 
2011 
IgA-NP 
MHC region rs3828890 6 31440669 0.11 -0.0079 0.0013 1.20E-
09 
Okada 
2012 
eGFRcrea 
HLA region rs3115573 6 32218843 0.45 1.62 1.39-1.90 1.00E-
09 
Feehally 
2010 
IgA-NP 
HLA-A rs2523946 6 29941943 0.5 0.82644628
1 
0.78-0.87 1.74E-
11 
Yu 2011 IgA-NP 
RSPO3 rs1936800 6 127477757 0.5 0.0052 0.0008 1.20E-
11 
Okada 
2012 
BUN 
SLC22A2 rs2279463 6 160668389 0.12 -0.013 0.002 5.50E-
12 
Köttgen 
2010 
eGFRcrea 
TAP1/2/PSMB8/
9 
rs9357155 6 32809848 0.2 0.71  2.11E-
12 
Gharavi 
2011 
IgA-NP 
HLA-DQA/B rs1794275 6 32671248 0.15 1.3 1.21-1.39 3.43E-
13 
Yu 2011 IgA-NP 
VEGFA rs881858 6 43806609 0.28 0.011 0.002 9.40E-
14 
Köttgen 
2010 
eGFRcrea 
HLA-DQB1 rs9275424 6 32702799 NA NA NA 4.00E-
14 
Kiryluk 
2012 
IgA-NP 
HLA-DQA1 rs1129740 6 32609105 0.49 2.11  2.14E-
19 
Gbadegesi
n 2015 
SSNS 
HLA-DRB1 rs660895 6 32577380 0.24 1.34 1.26-1.42 4.13E-
20 
Yu 2011 IgA-NP 
HLA-DQB1 rs9275596 6 32681631 0.22 0.63  1.59E-
26 
Gharavi 
2011 
IgA-NP 
HLA-DR–HLA-
DQ 
rs7763262 6 32424882 0.31 0.70921985
8 
0.67-0.75 1.80E-
38 
Kiryluk 
2014 
IgA-NP 
HLA-DQA1 rs2187668 6 32605884 0.13 4.32 3.73-5.01 8.00E-
93 
Stanescu 
2011 
IMN 
KBTBD2 rs3750082 7 32919927 0.33 0.0045 0.0008 3.22E-
08 
Pattaro 
2015 
eGFRcrea 
UNCX rs1027504
4 
7 1240371 0.34 0.0069 0.0012 4.30E-
09 
Okada 
2012 
BUN 
TMEM60 rs6465825 7 77416439 0.39 -0.008 0.001 1.50E-
09 
Köttgen 
2010 
eGFRcrea 
RNF32 rs6459680 7 156,258,56
8 
0.26 0.0055 0.0009 1.07E-
09 
Pattaro 
2015 
eGFRcrea 
UNCX rs1027711
5 
7 1285195 0.35 -0.0058 0.0009 1.00E-
10 
Okada 
2012 
eGFRcrea 
PRKAG2 rs7805747 7 151.407.80
1 
0.24 1.19 1.13-1.25 4.20E-
12 
Köttgen 
2010 
CKD 
STC1 rs1010941
4 
8 23751151 0.42 -0.008 0.001 1.00E-
08 
Köttgen 
2010 
eGFRcrea 
KLF10/ODF1 rs2033562 8 103547739 0.48 0.88495575
2 
0.85-0.92 1.41E-
09 
Li 2015 IgA-NP 
DEFA rs1008656
8 
8 6900336 0.33 1.16 1.11-1.22 1.00E-
09 
Kiryluk 
2014 
IgA-NP 
DEFA rs9314614 8 6697731 0.36 1.14 1.09-1.18 9.48E-
10 
Li 2015 IgA-NP 
DEFA rs2738048 8 6822785 0.32 0.79 0.74-0.84 3.80E-
14 
Yu 2011 IgA-NP 
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DEFA rs1271664
1 
8 6898998 0.257 0.81300813 0.77-0.85 1.13E-
18 
Li 2015 IgA-NP 
CARD9 rs4077515 9 139266496 0.4 1.16 1.11-1.22 1.20E-
09 
Kiryluk 
2014 
IgA-NP 
PIP5K1B rs4744712 9 71434707 0.39 -0.008 0.001 8.30E-
14 
Köttgen 
2010 
eGFRcrea 
WDR37 rs1079472
0 
10 1156165 0.08 -0.014 0.002 1.20E-
08 
Köttgen 
2010 
eGFRcrea 
CUBN rs1801239 10 16919052 0.098
5 
0.0835  1.10E-
11 
Böger 
2011 
CUBN 
A1CF rs1099486
0 
10 52645424 0.19 0.0077 0.0011 1.07E-
12 
Pattaro 
2015 
eGFRcrea 
ACCS rs2074038 11 44087989 0.29 1.14 1.09-1.19 3.93E-
09 
Li 2015 IgA-NP 
KCNQ1 rs163160 11 2789955 0.18 -0.0065 0.0011 2.26E-
09 
Pattaro 
2015 
eGFRcrea 
AP5B1 rs4014195 11 65506822 0.36 -0.0055 0.0008 1.10E-
11 
Pattaro 
2015 
eGFRcrea 
MPPED2-DCDC5 rs1076787
3 
11 30725254 0.69 0.0068 0.0008 4.50E-
16 
Okada 
2012 
BUN 
MPPED2 rs3925584 11 30760335 0.46 0.0075 0.0009 8.40E-
18 
Pattaro 
2012 
eGFRcrea 
INHBC rs1106766 12 57809456 0.22 0.0061 0.001 2.41E-
09 
Pattaro 
2015 
eGFRcrea 
C12orf51 rs2074356 12 111129784 0.23 0.0064 0.0011 1.80E-
09 
Okada 
2012 
BUN 
SLC6A13 rs1077402
1 
12 349298 0.36 0.008 0.001 1.40E-
09 
Köttgen 
2010 
eGFRcrea 
CUX2, 
FAM109A,  
SH2B3,  ATXN2, 
BRAP,  
ACAD10,  
ALDH2 
rs653178 12 112007756 0.5 0.003 0.001 3.50E-
11 
Köttgen 
2010 
eGFRcys 
PTPRO rs7956634 12 15321194 0.19 0.0068 0.001 7.17E-
12 
Pattaro 
2015 
eGFRcrea 
TSPAN9 rs1049196
7 
12 3368093 0.1 -0.0095 0.0013 5.18E-
14 
Pattaro 
2015 
eGFRcrea 
DACH1 rs626277 13 72347696 0.4 0.009 0.001 2.50E-
11 
Köttgen 
2010 
eGFRcrea 
INO80 rs2928148 15 41401550 0.48 -0.0051 0.0009 4.00E-
08 
Pattaro 
2012 
eGFRcrea 
no gene in <250 
kb  distance 
rs1243785
4 
15 94141833 0.038 1.8 1.48-2.17 2.00E-
09 
Sandholm 
2012 
T1-ESRD 
WDR72 rs491567 15 53946593 0.22 0.009 0.002 2.70E-
13 
Köttgen 
2010 
eGFRcrea 
UBE2Q2 rs1394125 15 76158983 0.35 -0.009 0.001 3.30E-
17 
Köttgen 
2010 
eGFRcrea 
GATM/SPATA5L
1 
rs2467853 15 45698793 0.62 0.0126 0.0009 1.05E-
42 
Pattaro 
2015 
CKD 
DPEP1 rs164748 16 89708292 0.47 -0.0046 0.0008 1.95E-
08 
Pattaro 
2015 
eGFRcrea 
PDILT rs1186490
9 
16 20400839 0.81 -0.0062 0.0011 3.60E-
10 
Okada 
2012 
eGFRcrea 
ITGAM-ITGAX rs1115061
2 
16 31357760 0.36 1.18 1.12-1.24 1.30E-
11 
Kiryluk 
2014 
IgA-NP 
UMOD rs1291770
7 
16 20367690 0.18 0.8 0.75-0.85 2.30E-
12 
Köttgen 
2009 
CKD 
ITGAM-ITGAX rs1157463
7 
16 31368874 0.18 0.75757575
8 
0.70-0.82 8.10E-
13 
Kiryluk 
2014 
IgA-NP 
SLC47A1 rs2453580 17 19438321 0.41 -0.0059 0.001 2.10E-
09 
Pattaro 
2012 
eGFRcrea 
BCAS3 rs1186844
1 
17 56594003 0.75 0.0059 0.001 2.10E-
09 
Okada 
2012 
BUN 
MPDU1 rs4227 17 7491177 0.24 1.23 1.16-1.32 4.31E-
10 
Yu 2011 IgA-NP 
TNFSF13 rs3803800 17 7462969 0.35 1.21 1.14-1.28 9.40E-
11 
Yu 2011 IgA-NP 
CDK12 rs1107890
3 
17 37631924 0.24 0.0096 0.0013 9.00E-
13 
Pattaro 
2012 
eGFRcrea 
BCAS3 rs9895661 17 59456589 0.19 -0.011 0.002 1.10E-
15 
Köttgen 
2010 
eGFRcrea 
NFATC1 rs8091180 18 77164243 0.44 0.006 0.001 1.28E-
09 
Pattaro 
2015 
eGFRcrea 
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SLC14A2 rs7227483 18 41441128 0.8 0.0083 0.001 6.70E-
18 
Okada 
2012 
BUN 
SIPA1L3 rs1166649
7 
19 38464262 0.18 -0.0058 0.0011 4.25E-
08 
Pattaro 
2015 
eGFRcrea 
SLC7A9 rs1246087
6 
19 33356891 0.39 0.008 0.001 3.20E-
15 
Köttgen 
2010 
eGFRcrea 
MKKS, SLX4IP,  
JAG1 
rs6040055 20 10633313 0.39 -0.017 0 1.00E-
08 
Köttgen 
2009 
eGFRcrea 
GNAS rs6026584 20 56902468 0.32 0.0052 0.0009 8.80E-
09 
Okada 
2012 
BUN 
TP53INP2 rs6088580 20 33285053 0.47 -0.0049 0.0008 1.79E-
09 
Pattaro 
2015 
eGFRcrea 
BCAS1 rs1721670
7 
20 52732362 0.21 0.0077 0.001 8.83E-
15 
Pattaro 
2015 
eGFRcrea 
NAPB, CSTL1,  
CST11, CST8,  
CST9L, CST9,  
CST3, CST4,  
CST1, CST2, 
CST5 
rs1303830
5 
20 23610262 0.21 0.076 0.004 2.20E-
88 
Köttgen 
2009 
eGFRcys 
APOL1 rs4821475 22 36669095 0.79 NA NA 3.51E-
08 
Genovese 
2010 
FSGS 
MYH9 rs2157256 22 36311616 0.91 NA NA 1.36E-
09 
Genovese 
2010 
FSGS 
APOL2 rs4821469 22 36220399 0.8 NA NA 9.31E-
10 
Genovese 
2010 
FSGS 
MYH9 rs1699667
2 
22 36329925 0.56 NA NA 2.56E-
10 
Genovese 
2010 
FSGS 
MTMR3 rs12537 22 30423460 0.16 0.78 0.72-0.84 1.17E-
11 
Yu 2011 IgA-NP 
APOL1 rs2239785 22 36265284 0.94 NA NA 4.59E-
13 
Genovese 
2010 
FSGS 
This table is restricted to single nucleotipe polymorphisms (SNPs) that reached genome-wide significance (p<5E-08). Associated loci are 
reported from the study in which they were identified with lowest p-value. The same locus is only reported from a subsequent study if the 
index SNP in the later study is in low LD with the previously reported index SNP (r2<0.2 in the corresponding 1000 Genomes population). If 
SNPs within an associated locus showed independent evidence for association by conditional analyses, all independent index SNPs within 
the locus are reported.  
Gene Symbols, Official gene symbol; SNP, SNP ID; Chr, chromosome number; Pos (b37), chromosome position; Freq, for case-control 
studies, the minor allele frequency in controls is presented. If available, the combined frequency (discovery+replication) is used; otherwise, 
the frequency in the discovery group is reported; Effect Size,the effect estimate is reported with respect to the minor allele; Combined effect 
estimates (beta/OR, SE/95% CI, p-value) from discovery + replication were used when available. Otherwise, effect estimates for the 
discovery sample are shown; 95%CI, 95% confidence interval; p-value, raw p-value; Reference, GWAS Publication where it is found, all 
papers are cited in Chapter 2; Association parameter, disease that was reported to have a GWAS hit for the disease. 
 
Please see supplementary digital files for appendix 2-6. 
Appendix 2 | All significant eGenes 
Appendix 3 | Differentially methylated loci and the corresponding differentially expressed 
transcripts 
Appendix 4 | Infinium DKD dataset and HELP CKD dataset differentially methylated loci 
Appendix 5 | Technical validation of methylation level using MassArray Epityper 
Appendix 6 | RefSeq annotated genomic distribution of the hypo- and hypermethylated 
regions  
Appendix 7 | List of differentially methylated regions with p-value methylation level, 
genomic locus and nearest annotated transcript 
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